Policy Statement

I. Unilateral deep brain stimulation of the thalamus may be considered medically necessary in individuals with disabling, medically unresponsive tremor due to essential tremor or Parkinson disease.

II. Bilateral deep brain stimulation of the thalamus may be considered medically necessary in individuals with disabling, medically unresponsive tremor in both upper limbs due to essential tremor or Parkinson disease.

III. Unilateral or bilateral deep brain stimulation of the globus pallidus or subthalamic nucleus may be considered medically necessary in the following individuals:
   A. Those with Parkinson disease and all of the following:
      1. A good response to levodopa
      2. Motor complications not controlled by pharmacologic therapy
      3. One of the following:
         a. A minimum score of 30 points on the motor portion of the Unified Parkinson Disease Rating Scale when the patient has been without medication for approximately 12 hours
         b. Parkinson disease for at least 4 years
   B. Individuals older than 7 years with chronic, intractable (drug-refractory) primary dystonia, including generalized and/or segmental dystonia, hemidystonia, and cervical dystonia (torticollis)

IV. Deep brain stimulation for other movement disorders, including but not limited to tardive dyskinesia and post-traumatic dyskinesia, is considered investigational.

V. Deep brain stimulation for the treatment of chronic cluster headaches is considered investigational.

VI. Deep brain stimulation for the treatment of other psychiatric or neurologic disorders, including but not limited to epilepsy, Tourette syndrome, depression, obsessive–compulsive disorder, anorexia nervosa, alcohol addiction, Alzheimer disease, multiple sclerosis tremor, and chronic pain, is considered investigational.

NOTE: Refer to Appendix A to see the policy statement changes (if any) from the previous version.

Policy Guidelines

Disabling, medically unresponsive tremor is defined as all of the following:
- Tremor causing significant limitation in daily activities
- Inadequate control by maximal dosage of medication for at least 3 months before implant

Contraindications to deep brain stimulation include:
- Individuals who are not good surgical risks because of unstable medical problems or because of the presence of a cardiac pacemaker
- Individuals who have medical conditions that require repeated magnetic resonance imaging
- Individuals who have dementia that may interfere with the ability to cooperate
• Individuals who have had botulinum toxin injections within the last 6 months

Description

Deep brain stimulation involves the stereotactic placement of an electrode into a central nervous system nucleus (e.g., hypothalamus, thalamus, globus pallidus, subthalamic nucleus). Deep brain stimulation is used as an alternative to permanent neuroablative procedures for control of essential tremor and Parkinson disease. Deep brain stimulation is also being evaluated for the treatment of a variety of other neurologic and psychiatric disorders.

Related Policies

• Responsive Neurostimulation for the Treatment of Refractory Focal Epilepsy

Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

Regulatory Status

In 1997, the Activa® Tremor Control System (Medtronic) was approved by the U.S. Food and Drug Administration (FDA) through the pre-market approval process for deep brain stimulation. The Activa Tremor Control System consists of an implantable neurostimulator, a deep brain stimulator lead, an extension that connects the lead to the power source, a console programmer, a software cartridge to set electrical parameters for stimulation, and a patient control magnet, which allows the patient to turn the neurostimulator on and off, or change between high and low settings.

The FDA labeled indications for Activa were originally limited to unilateral implantation for the treatment of tremor, but the indications have evolved over time. In 2002, the FDA labeled indications were expanded to include bilateral implantation as a treatment to decrease the symptoms of advanced Parkinson disease not controlled by medication. In 2003, the labeled indications were further expanded to include “…unilateral or bilateral stimulation of the internal globus pallidus or subthalamic nucleus to aid in the management of chronic, intractable (drug refractory) primary dystonia, including generalized and/or segmental dystonia, hemidystonia, and cervical dystonia (torticollis) in patients 7 years of age or above.” In 2018, the deep brain stimulation system received an expanded indication as an adjunctive therapy for epilepsy (P960009-S219). Other deep brain stimulation systems are described in Table 1.

Table 1. Deep Brain Stimulation Systems

<table>
<thead>
<tr>
<th>System</th>
<th>Manufacturer</th>
<th>FDA Product Code</th>
<th>PMA or HDE</th>
<th>Approval Date</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activa® Deep Brain Stimulation Therapy System</td>
<td>Medtronic</td>
<td>MBX</td>
<td>P96009</td>
<td>1997</td>
<td>Unilateral or bilateral stimulation of the internal globus</td>
</tr>
<tr>
<td>System</td>
<td>Manufacturer</td>
<td>FDA Product Code</td>
<td>PMA or HDE</td>
<td>Approval Date</td>
<td>Indications</td>
</tr>
<tr>
<td>---------------------------------------------</td>
<td>-------------------------------------</td>
<td>------------------</td>
<td>------------</td>
<td>---------------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Reclaim® DBS Therapy for Obsessive Compulsive Disorder</td>
<td>Medtronic</td>
<td>H050003</td>
<td>2009</td>
<td>Bilateral stimulation of the anterior limb of the internal capsule for severe obsessive-compulsive disorder</td>
<td></td>
</tr>
<tr>
<td>Brio Neurostimulation System</td>
<td>St. Jude Medical</td>
<td>NHL</td>
<td>P140009</td>
<td>2015</td>
<td>Parkinsonian tremor (subthalamic nucleus) and essential tremor (thalamus)</td>
</tr>
<tr>
<td>Infinity DBS</td>
<td>Abbott Medical/St. Jude Medical</td>
<td>PJS</td>
<td>P140009</td>
<td>2016</td>
<td>Parkinsonian tremor</td>
</tr>
<tr>
<td>Vercise DBS System</td>
<td>Boston Scientific</td>
<td>NHL</td>
<td>P150031</td>
<td>2017</td>
<td>Moderate-to-advanced levodopa-responsive PD inadequately controlled with medication alone</td>
</tr>
<tr>
<td>Medtronic DBS System for Epilepsy</td>
<td>Medtronic</td>
<td>MBX</td>
<td>P960009-S219</td>
<td>2018</td>
<td>Expanded indication for epilepsy with bilateral stimulation of the anterior nucleus of the thalamus</td>
</tr>
<tr>
<td>Percept PC Deep Brain Stimulation</td>
<td>Medtronic</td>
<td>MHY</td>
<td>P960009-S</td>
<td>2020</td>
<td>Records brain signals while delivering therapy for PD or primary dystonia</td>
</tr>
<tr>
<td>Vercise Genus DBS System</td>
<td>Boston Scientific</td>
<td>NHL</td>
<td>P150031-S034</td>
<td>2021</td>
<td>Stimulation of the subthalamic nucleus and globus pallidus for PD</td>
</tr>
<tr>
<td>SenSight Directional Lead System</td>
<td>Medtronic</td>
<td>MHY</td>
<td>P960009</td>
<td>2021</td>
<td>Unilateral or bilateral stimulation for PD, tremor, dystonia, and epilepsy</td>
</tr>
</tbody>
</table>

DBS: deep brain stimulation; HDE: humanitarian device exemption; PD: Parkinson disease; PMA: premarket approval
Rationale

Background

Deep Brain Stimulation

Deep brain stimulation involves the stereotactic placement of an electrode into the brain (i.e., hypothalamus, thalamus, globus pallidus, or subthalamic nucleus). The electrode is initially attached to a temporary transcutaneous cable for short-term stimulation to validate treatment effectiveness. Several days later, the patient returns for permanent subcutaneous surgical implantation of the cable and a radiofrequency-coupled or battery-powered programmable stimulator. The electrode is typically implanted unilaterally on the side corresponding to the most severe symptoms. However, use of bilateral stimulation using 2 electrode arrays has also been investigated in patients with bilateral, severe symptoms. After implantation, noninvasive programming of the neurostimulator can be adjusted to the patient’s symptoms. This feature may be important for patients with Parkinson disease, whose disease may progress over time, requiring different neurostimulation parameters. Setting the optimal neurostimulation parameters may involve the balance between optimal symptom control and appearance of adverse effects of neurostimulation, such as dysarthria, disequilibrium, or involuntary movements.

Literature Review

Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function, including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent 1 or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized controlled trials are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Promotion of greater diversity and inclusion in clinical research of historically marginalized groups (e.g., People of Color [African-American, Asian, Black, Latino and Native American]; LGBTQIA [Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, Asexual]; Women; and People with Disabilities [Physical and Invisible]) allows policy populations to be more reflective of and findings more applicable to our diverse members. While we also strive to use inclusive language related to these groups in our policies, use of gender-specific nouns (e.g., women, men, sisters, etc.) will continue when reflective of language used in publications describing study populations.

Essential Tremor and Tremor in Parkinson Disease

Clinical Context and Therapy Purpose

Deep brain stimulation has been investigated as an alternative to permanent neuroablative procedures, such as thalamotomy and pallidotomy, and pharmacologic therapy. Deep brain stimulation has been most thoroughly investigated as an alternative to thalamotomy for unilateral control of essential tremor and tremor associated with Parkinson disease. In addition, levodopa, the most commonly used anti-Parkinson drug, may be associated with disabling drug-induced
dyskinesias. Therefore, the optimal pharmacologic treatment of Parkinson disease may involve a balance between optimal effects on Parkinson disease symptoms and the appearance of drug-induced dyskinesias. The effect of deep brain stimulation on both Parkinson disease symptoms and drug-induced dyskinesias has also been studied.

The following PICO was used to select literature to inform this review.

**Populations**
The relevant populations of interest are individuals with essential tremor or tremor in Parkinson disease.

**Interventions**
The therapy being considered is deep brain stimulation, unilateral or bilateral stimulation of the thalamus.

**Comparators**
Parkinson disease is usually treated with medications. Permanent neuroablative procedures (e.g., thalamotomy, pallidotomy) may be considered in people who respond poorly to medication, have severe side-effects, or have severe fluctuations in response to medication.

**Outcomes**
Key efficacy outcomes include motor scores, mobility, disability, activities of daily living (ADL), and quality of life. Key safety outcomes include death, stroke, depression, cognition, infection, and other device and procedure related events. Length of follow-up was up to 5 years.

**Study Selection Criteria**
Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

**Review of Evidence**

**Unilateral Stimulation of the Thalamus**
This section was informed by a TEC Assessment (1997) that focused on unilateral deep brain stimulation of the thalamus as a treatment of tremor. The Assessment concluded:

- Tremor suppression was totally or clinically significant in 82% to 91% of operated sides in 179 patients who underwent implantation of thalamic stimulation devices. Results were durable for up to 8 years, and adverse events of stimulation were reported as mild and largely reversible.
- These results were at least as good as those associated with thalamotomy. An additional benefit of deep brain stimulation is that recurrence of tremor may be managed by changes in stimulation parameters.

Studies identified in subsequent literature searches have supported the conclusions of the TEC Assessment. For example, Schuurman et al (2008) reported on 5-year follow-up of 68 patients comparing thalamic stimulation with thalamotomy for treatment of tremor due to Parkinson disease (n=45 patients), essential tremor (n=13 patients), and multiple sclerosis (MS; n=10 patients). Forty-eight (71%) patients were assessed at 5 years: 32 with Parkinson disease, 10 with essential tremor, and 6 with MS. The Frenchay Activities Index, the primary study outcome measure, was used to assess
change in functional status; secondary measures included tremor severity, complication frequency, and patient-assessed outcomes. The mean difference (MD) between interventions, as measured on the Frenchay Activities Index, favored thalamic stimulation at all time points: 4.4 (95% confidence interval [CI], 1.1 to 7.7) at 6 months, 3.3 (95% CI, -0.03 to 6.6) at 2 years, and 4.0 (95% CI, 0.3 to 7.7) at 5 years. The procedures had similar efficacy for suppressing tremors. The effect of thalamic stimulation diminished in half of the patients with essential tremor and MS. Neurologic adverse effects were higher after thalamotomy. Subjective assessments favored stimulation.

Hariz et al (2008) evaluated outcomes of thalamic deep brain stimulation in patients with tremor-predominant Parkinson disease who participated in a multicenter European study; the authors reported that at 6 years postsurgery tremor was still effectively controlled and appendicular rigidity and akinesia remained stable compared with baseline.

**Bilateral Stimulation of the Thalamus**

**Observational Studies**

Putzke et al (2005) reported on a series of 25 patients with essential tremor treated with bilateral deep brain stimulation for management of midline tremor (head, voice, tongue, trunk). Three patients died of unrelated causes, 1 patient was lost to follow-up due to transfer of care, and 1 patient did not have baseline evaluation; these patients were not included in the analysis. Patients were evaluated at baseline (before implantation of second stimulator), and at 1, 3, 6, 12, 24, and 36 months. At 12 months, evaluations were obtained from 76% of patients; at 36 months, 50% of patients were evaluated. The most consistent improvement on the Tremor Rating Scale during both unilateral and bilateral stimulation was found for head and voice tremor. The incremental improvement over unilateral stimulation through the first 12 months of bilateral stimulation was significant (p<.01). For bilateral stimulation at months 3 and 12, outcome measures were significantly better than unilateral stimulation at month 3 (p<.05). Limited sample size precludes interpretation at months 24 and 36. Dysarthria was reported in 6 (27%) patients and disequilibrium in 5 (22%) patients after bilateral stimulation in staged implantations. No patient reported dysarthria and 2 reported disequilibrium before bilateral stimulation.

Pahwa et al (2006) reported on long-term follow-up of 45 patients who underwent thalamic deep brain stimulation, 26 of whom had essential tremor; of these patients, 18 had unilateral and 8 had bilateral implantation. Sixteen patients with unilateral and 7 with bilateral stimulators completed at least part of the 5 year follow-up evaluations. Patients with bilateral stimulation had a 78% improvement in mean motor tremor scores in the stimulation on state compared with baseline at 5 year follow-up (p=.02) and 36% improvement in ADL scores. Patients with unilateral stimulation improved by 46% on motor tremor scores and 51% on ADL scores (p<.01). Stimulation-related adverse events were reported in more than 10% of patients with unilateral and bilateral thalamic stimulators. Most were mild and were reduced with changes in stimulation parameters. Adverse events in patients with bilateral stimulation (e.g., dysarthria and other speech difficulties, disequilibrium or balance difficulties, abnormal gait) persisted, despite optimization of the stimulation parameters.

**Directional Deep Brain Stimulation**

**Randomized Controlled Trial**

Three new deep brain stimulation systems with directional leads are currently available (approved by the U.S. Food and Drug Administration [FDA] in 2016, 2017, and 2021). Directional leads potentially enable clinicians to target more specific areas of the brain to be treated with the direct current. Schnitzler et al (2022) conducted a prospective crossover study with randomized, double-blind endpoint evaluation in 234 patients with Parkinson disease. All patients received conventional deep brain stimulation for 3 months followed by directional deep brain stimulation for 3 months. The therapeutic window was wider after using directional stimulation in 90.6% of patients, with a mean increase of 41% compared to conventional deep brain stimulation.
Section Summary: Essential Tremor and Tremor in Parkinson Disease
A TEC Assessment concluded there was sufficient evidence that deep brain stimulation of the thalamus results in clinically significant tremor suppression and that outcomes after deep brain stimulation were at least as good as thalamotomy. Subsequent studies reporting long-term follow-up have supported the conclusions of the TEC Assessment and found that tremors were effectively controlled 5 to 6 years after deep brain stimulation. A new technology in deep brain stimulation systems, using directional leads, has more recently emerged.

Symptoms Associated with Parkinson Disease

Clinical Context and Therapy Purpose
The purpose of deep brain stimulation is to provide a treatment option that is an alternative to or an improvement on existing therapies for individuals with symptoms associated with Parkinson disease. More recently, there has been research interest in the use of deep brain stimulation of the globus pallidus or subthalamic nucleus as a treatment of other Parkinsonian symptoms, such as rigidity, bradykinesia, and akinesia.

The following PICO was used to select literature to inform this review.

**Populations**
The relevant populations of interest are individuals with symptoms associated with Parkinson disease.

**Interventions**
The therapy being considered is deep brain stimulation of the internal segment of the globus pallidus interna and subthalamic nucleus.

**Comparators**
The following practice is currently being used to treat Parkinson disease: pharmacologic therapy and physical and speech therapy.

**Outcomes**
Key efficacy outcomes include motor scores, mobility, disability, ADL, and quality of life. Key safety outcomes include death, stroke, depression, cognition, infection, and other device and procedure related events. Length of follow-up was up to 4 years.

**Study Selection Criteria**
Methodologically credible studies were selected using the following principles:
- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Review of Evidence

Advanced Parkinson Disease

Stimulation of the Internal Segment of the Globus Pallidus Interna and Subthalamic Nucleus
This section was informed by a TEC Assessment (2001) that focused on the use of deep brain stimulation of the internal segment of the globus pallidus interna and subthalamic nucleus for a broader range of Parkinson disease symptoms. The Assessment concluded:
A wide variety of studies have consistently demonstrated that deep brain stimulation of the globus pallidus interna or subthalamic nucleus results in significant improvements, as measured by standardized rating scales of neurologic function. The most frequently observed improvements consist of increased waking hours spent in a state of mobility without dyskinesia, improved motor function during “off” periods when levodopa is not effective, reduction in frequency and severity of levodopa-induced dyskinesia during periods when levodopa is working (“on” periods), improvement in cardinal symptoms of Parkinson disease during periods when medication is not working, and in the case of bilateral deep brain stimulation of the subthalamic nucleus, reduction in the required daily dosage of levodopa and/or its equivalents. The magnitude of these changes were both statistically significant and clinically meaningful.

The beneficial treatment effect lasted at least for the 6 to 12 months observed in most trials. While there was limited long-term follow-up, the available data were generally positive.

Adverse effects and morbidity were similar to those known to occur with thalamic stimulation.

Deep brain stimulation possesses advantages to other treatment options. Compared with pallidotomy, deep brain stimulation can be performed bilaterally. The procedure is nonablative and reversible.

Systematic Reviews

A systematic review of RCTs by Perestelo-Perez et al (2014) compared the impact of deep brain stimulation plus medication with medication alone (or plus sham deep brain stimulation) on Parkinson disease outcomes. Six RCTs (N=1,184 patients) were included in the review. Five trials exclusively involved bilateral stimulation to the subthalamic nucleus and, in the sixth trial, half of the patients received stimulation to the subthalamic nucleus and the other half had stimulation to the globus pallidus interna. Motor function assessment was blinded in 2 trials and the randomization method was described in 4 trials. Five studies reported motor function, measured by the Unified Parkinson's Disease Rating Scale-III. In the off-medication phase, motor function was significantly higher with deep brain stimulation than with control (weighted MD, 15.20; 95% CI, 12.23 to 18.18; standard MD, 1.35). In the on-medication phase, there was also significantly greater motor function with deep brain stimulation than with control (weighted MD, 4.36; 95% CI, 2.80 to 5.92; standard MD, 0.53). Meta-analyses of other outcomes (e.g., ADLs, quality of life, dementia, depression) also favored the deep brain stimulation group.

An earlier systematic review by Kleiner-Fisman et al (2006) included both RCTs and observational studies; reviewers examined the literature on subthalamic stimulation for patients with Parkinson disease who had failed medical management. Twenty studies, primarily uncontrolled cohorts or case series, were included in the meta-analysis. Subthalamic stimulation was found to improve ADLs by 50% over baseline, as measured by the Unified Parkinson's Disease Rating Scale-II (decrease of 13.35 points out of 52). There was a 28-point decrease in the Unified Parkinson's Disease Rating Scale-III score (out of 108), indicating a 52% reduction in the severity of motor symptoms that occurred while the patient was not taking medication. A strong relationship was found between the preoperative dose response to levodopa and improvements in both the Unified Parkinson's Disease Rating Scale-II and -III scores. The analysis found a 56% reduction in medication use, a 69% reduction in dyskinesia, and a 35% improvement in quality of life with subthalamic stimulation. A meta-analysis by Appleby et al (2007) found that the rate of suicidal ideation and suicide attempts associated with deep brain stimulation for Parkinson disease ranged from 0.3% to 0.7%. The completed suicide rate ranged from 0.16% to 0.32%. In light of the rate of suicide in patients treated with deep brain stimulation, reviewers argued for prescreening for suicide risk.

Parkinson Disease With Early Motor Complications

Randomized Controlled Trial

Schuepbach et al (2013) published an RCT evaluating deep brain stimulation in patients with Parkinson disease and early motor complications. Key eligibility criteria included age 18 to 60 years, disease duration of at least 4 years, improvement of motor signs of at least 50% with dopaminergic
medication, and Parkinson disease severity below stage 3 in the on-medication condition. A total of 251 patients enrolled, 124 of whom were assigned to deep brain stimulation plus medical therapy and 127 to medical therapy alone. Analysis was intention to treat and blinded outcome assessment was done at baseline and 2 years.

The primary endpoint was mean change from baseline to 2 years in the summary index of the Parkinson Disease Questionnaire, which has a maximum score of 39 points, with higher scores indicating higher quality of life. Mean baseline scores on the Parkinson Disease Questionnaire were 30.2 in the deep brain stimulation plus medical therapy group and 30.2 in the medical therapy only group. At 2 years, the mean score increased by 7.8 points in the deep brain stimulation plus medical therapy group and decreased by 0.2 points in the medical therapy only group (mean change between groups, 8.0; p=.002). There were also significant between-group differences in major secondary outcomes, favoring the deep brain stimulation plus medical therapy group (p<.01 on each): severity of motor signs, ADLs, severity of treatment-related complications, and the number of hours with good mobility and no troublesome dyskinesia. The first 3 secondary outcomes were assessed using Unified Parkinson’s Disease Rating Scale subscales. Regarding medication use, the levodopa-equivalent daily dose was reduced by 39% in the deep brain stimulation plus medical therapy group and increased by 21% in the medical therapy only group.

Sixty-eight patients in the deep brain stimulation plus medical therapy group, and 56 in the medical therapy only group, experienced at least 1 serious adverse event. This included 26 serious adverse events in the deep brain stimulation group that were surgery- or device-related; reoperation was necessary in 4 patients.

**Globus Pallidus Interna Versus Subthalamic Nucleus Stimulation Systematic Reviews**

A number of meta-analyses have compared the efficacy of globus pallidus interna with subthalamic nucleus stimulation in Parkinson disease patients.12-18 The meta-analysis by Tan et al (2016) included only RCTs comparing the 2 types of stimulation in patients with advanced Parkinson disease and considered a range of outcomes.14 This review included RCTs evaluating patients with Parkinson disease who were responsive to levodopa, had at least 6 months of follow-up, and reported at least 1 of the following outcome measures: Unified Parkinson’s Disease Rating Scale-III, Beck Depression Inventory-II, levodopa-adjusted dose, neurocognitive status, or quality of life. Ten RCTs met eligibility criteria and were included in the quantitative synthesis. After 6 months, there were no significant differences in the Unified Parkinson’s Disease Rating Scale-III scores between the globus pallidus interna and subthalamic nucleus groups for patients in the off-medication/on-stimulation state (5 studies; MD, -1.39; 95% CI, -3.70 to 0.92) or the on-medication/on-stimulation state (5 studies; MD, -0.37; 95% CI, -2.48 to 1.73). At the 12- and 24-month follow-ups, only 1 to 3 studies reported data on the Unified Parkinson’s Disease Rating Scale-III score. In a pooled analysis of the levodopa-adjusted dose, there was a significant difference between the globus pallidus interna and subthalamic nucleus groups, favoring subthalamic nucleus (6 studies; MD, 0.60; 95% CI, 0.46 to 0.74). However, the analysis of Beck Depression Inventory II scores favored the globus pallidus interna group (4 studies; MD, -0.31; 95% CI, -0.51 to -0.12). Other meta-analyses had similar mixed findings and none concluded that 1 type of stimulation was clearly better than the other for patients with advanced Parkinson disease.

**Section Summary: Symptoms Associated With Parkinson Disease**

A number of RCTs and systematic reviews of the literature have been published. A TEC Assessment concluded that studies evaluating deep brain stimulation of the globus pallidus interna or subthalamic nucleus have consistently demonstrated clinically significant improvements in outcomes (e.g., neurologic function). Other systematic reviews have also found significantly better outcomes after deep brain stimulation than after a control intervention. One RCT compared deep brain stimulation plus medical therapy with medical therapy alone in patients with levodopa-responsive Parkinson disease of at least 4 years in duration and uncontrolled motor symptoms. The trial found
that quality of life at 2 years (e.g., motor disability, motor complications) was significantly higher when deep brain stimulation was added to medical therapy. Meta-analyses of RCTs comparing globus pallidus interna and subthalamic nucleus have had inconsistent findings and did not conclude that 1 type of stimulation was clearly superior to the other.

Primary Dystonia
Clinical Context and Therapy Purpose
Deep brain stimulation has also been investigated in patients with primary and secondary dystonia, defined as a neurologic movement disorder characterized by involuntary muscle contractions, which force certain parts of the body into abnormal, contorted, and painful movements or postures. Dystonia can be classified according to age of onset, bodily distribution of symptoms, and cause. Age of onset can occur during childhood or during adulthood. Dystonia can affect certain portions of the body (focal dystonia and multifocal dystonia) or the entire body (generalized dystonia). Torticollis is an example of a focal dystonia.

Deep brain stimulation for the treatment of primary dystonia received FDA approval through the humanitarian device exemption process in 2003. The humanitarian device exemption approval process is available for conditions that affect fewer than 4,000 Americans per year. According to this approval process, the manufacturer is not required to provide definitive evidence of efficacy but only probable benefit. The approval was based on the results of deep brain stimulation in 201 patients represented in 34 manuscripts. Three studies reported at least 10 cases of primary dystonia. In these studies, clinical improvement with deep brain stimulation ranged from 50% to 88%. A total of 21 pediatric patients were studied; 81% were older than age 7 years. Among these patients, there was a 60% improvement in clinical scores.

The purpose of deep brain stimulation is to provide a treatment option that is an alternative to or an improvement on existing therapies for patients with primary dystonia.

The following PICO was used to select literature to inform this review.

**Populations**
The relevant population of interest are individuals with primary dystonia. Primary dystonia is defined when dystonia is the only symptom unassociated with other pathology.

**Interventions**
The therapy being considered is deep brain stimulation of the globus pallidus interna or subthalamic nucleus.

**Comparators**
The following practice is currently being used to treat primary dystonia: pharmacologic therapy or permanent neuroablative procedures (e.g., thalamotomy, pallidotomy). Treatment options for dystonia include oral or injectable medications (i.e., botulinum toxin) and destructive surgical or neurosurgical interventions (i.e., thalamotomies or pallidotomies) when conservative therapies fail.

As noted in the FDA humanitarian device exemption analysis of risk and probable benefit, the only other treatment options for chronic refractory primary dystonia are neurodestructive procedures. Deep brain stimulation provides a reversible alternative.

**Outcomes**
Key efficacy outcomes include clinical severity of dystonia and disability, rated using the Burke-Fahn-Marsden Dystonia Rating Scale or Toronto Western Spasmodic Torticollis Rating scale, and quality of life.
The Burke-Fahn-Marsden Dystonia Rating Scale total score ranges from 0 to 150. It has 2 subscales: a movement sub-scale, based on clinical patient examination, that assesses dystonia severity and provoking factors in different body areas, with a maximum score of 120; and a disability sub-scale, that evaluates the patient’s report of disability in activities of daily living, for a maximum score of 30. Higher scores correspond to greater levels of morbidity. There is currently no established minimally important difference in the Burke-Fahn-Marsden Dystonia Rating Scale total score.

Toronto Western Spasmodic Torticollis Rating scale is most commonly used to assess the status of people with cervical dystonia. The Toronto Western Spasmodic Torticollis Rating scale has a total score ranging from 0 to 85. It is a composite of 3 sub-scales: severity which ranges from 0 to 35; disability which ranges from 0 to 30; and pain which ranges from 0 to 20. Higher scores correspond to greater levels of morbidity.

Key safety outcomes include death, stroke, depression, cognition, infection and other device and procedure related events.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Review of Evidence
Primary Dystonia

Systematic Reviews
Moro et al (2017) published a systematic review of literature published through November 2015 on primary dystonia (also known as isolated dystonia). Reviewers included studies with at least 10 cases. Fifty-eight articles corresponding to 54 unique studies were identified; most involved bilateral deep brain stimulation of the globus pallidus interna. There were only 3 controlled studies, 2 RCTs (Kupsch et al [2006] and Volkmann et al [2014]; described below) and 1 study that included a double-blind evaluation with and without stimulation. Rodrigues et al (2019) performed a Cochrane systematic review of RCTs and identified the same 2 RCTs.

Randomized Controlled Trials
The 2 RCTs identified in the systematic reviews are described in Tables 2 through 5. Kupsch et al (2006) randomized 40 patients with primary segmental or generalized dystonia to deep brain stimulation or sham stimulation for 3 months. The primary outcome was change from baseline to 3 months in the severity of symptoms measured by the Burke-Fahn-Marsden Dystonia Rating Scale assessed by blinded reviewers from videotaped sessions. All patients subsequently received open-label deep brain stimulation for 6 months after blinded treatment. Results are shown in Table 2. In brief, the change from baseline in the mean Burke-Fahn-Marsden Dystonia Rating Scale movement score was significantly greater in the deep brain stimulation group.

The Volkmann et al (2014) RCT was patient- and observer-blinded evaluation of pallidal neurostimulation in subjects with refractory cervical dystonia. The primary outcome was change in the Toronto Western Spasmodic Torticollis Rating scale severity score at the end of the blinded study period (3 months); thereafter, all patients received open-label active stimulation. Results are shown in Table 3. There was significantly greater improvement in the neurostimulation group than in the sham group on the Toronto Western Spasmodic Torticollis Rating scale disability score and the Bain Tremor...
Scale score but not on the Toronto Western Spasmodic Torticollis Rating scale pain score or the Craniocervical Dystonia Questionnaire-24 score. During the 3 month blinded study period, 22 adverse events were reported in 20 (63%) patients in the neurostimulation group and 13 adverse events were reported in 12 (40%) patients in the sham group. Of these 35 adverse events, 11 (31%) were serious. Additionally, 40 adverse events, 5 of which were serious, occurred during 9 months of the open-label extension period. During the study, 7 patients experienced dysarthria (i.e., slightly slurred speech), which was not reversible in 6 patients.

Table 2. Characteristics of Randomized Controlled Trials of Deep Brain Stimulation for Primary Dystonia

<table>
<thead>
<tr>
<th>Study, Trial</th>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kupsch et al (2006) 22; NCT00142259</td>
<td>Germany, Norway, Austria</td>
<td>10</td>
<td>2002 to 2004</td>
<td>Patients ages 14 to 75 years with marked disability owing to primary generalized or segmental dystonia despite optimal pharmacologic treatment with disease duration of at least 5 years</td>
<td>n=20</td>
</tr>
<tr>
<td>Volkmann et al (2014) 23; NCT00148889</td>
<td>Germany, Norway, Austria</td>
<td>10</td>
<td>2006 to 2008</td>
<td>Adults under age of 75 with idiopathic or inherited isolated cervical dystonia with disease duration ≥3 years or longer, ≥15 on the TWSTRS, and an unsatisfactory response to botulinum toxin injection and oral medication</td>
<td>n=32</td>
</tr>
</tbody>
</table>

DBS: deep brain stimulation; GPi: globus pallidus internus; TWSTRS: Toronto Western Spasmodic Torticollis Rating Scale.

Table 3. Results of Randomized Controlled Trials of Deep Brain Stimulation for Primary Dystonia

<table>
<thead>
<tr>
<th>Study</th>
<th>Dystonia severity</th>
<th>Disability</th>
<th>Quality of life</th>
<th>Depression symptoms</th>
<th>Serious Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kupsch et al (2006) 22</td>
<td>Change in BFMDRS movement at 3 months, Mean (SD)</td>
<td>Change in BFMDRS disability at 3 months, Mean (SD)</td>
<td>Change in SF-36 at 3 months, Mean (SD)</td>
<td>Change in BDI at 3 months</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>40</td>
<td>39</td>
<td>33</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>DBS</td>
<td>-15.8 (14.1)</td>
<td>3.9 (2.9)</td>
<td>PCS: 10.1 (7.4)</td>
<td>MD=14.40 (8.0 to 20.80); p&lt;.01</td>
<td></td>
</tr>
<tr>
<td>Sham</td>
<td>-1.4 (3.8)</td>
<td>0.8 (1.2)</td>
<td>PCS: 3.8 (8.4)</td>
<td>MD=4.60 (-2.06 to 11.26)</td>
<td></td>
</tr>
<tr>
<td>Treatment effect (95% CI)</td>
<td>MD=14.40 (8.0 to 20.80); p&lt;.01</td>
<td>MD=3.10 (1.72 to 4.48)</td>
<td>PCS MD=6.30 (1.06 to 11.54)</td>
<td>MD=4.60 (-2.06 to 11.26)</td>
<td></td>
</tr>
<tr>
<td>Volkmann et al (2014) 23</td>
<td>Change in TWSTRS severity at 3 months</td>
<td>Change in TWSTRS disability at 3 months</td>
<td>Change in SF-36 at 3 months</td>
<td>Change in BDI at 3 months</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3 (8%)3 related to lead dislodgement or 1 related to infection requiring hospitalization</td>
</tr>
</tbody>
</table>
Study | Dystonia severity | Disability | Quality of life | Depression symptoms | Serious Adverse Events
---|---|---|---|---|---
N | 62 | 61 | 57 | 61 | 
DBS | -5.1 (5.1) | -5.6 (5.6) | PCS: 6.6 (21.9) | -3.5 (5.6) | 16 (26%), 11 related to surgery or device, 1 related to medication or stimulation, 4 related to dystonia
Sham | -1.3 (2.4) | -1.8 (3.8) | PCS: 3.6 (19.2) | -0.4 (3.7) | 

Treatment effect (95% CI) | MD=3.80 (1.84 to 5.76); p<.01 | MD=3.80 (1.41 to 6.19) | PCS MD=3.00 (-7.71 to 13.71) | MD=3.10 (0.73 to 5.47) |

BDI: Beck Depression Inventory; BFMDRS: Burke-Fahn-Marsden-Dystonia-Rating-Scale; CI: confidence interval; DBS: deep brain stimulation; MCS: Mental component score; MD: Mean difference; PCS: Physical Component Score; SD: standard deviation; SF-36: short form 36 item quality of life survey; TWSTRS: Toronto Western Spasmodic Torticollis Rating Scale.

Table 4. Study Relevance Limitations: Randomized Controlled Trials of Deep Brain Stimulation for Primary Dystonia

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcomes</th>
<th>Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kupsch et al (2006)</td>
<td>1: Only 3 months of double-blind study</td>
<td>1: Registered after enrollment was complete</td>
<td>1: Registered after enrollment was complete</td>
<td>1: Registered after enrollment was complete</td>
<td>1: Registered after enrollment was complete</td>
</tr>
<tr>
<td>Volkman et al (2014)</td>
<td>1: Only 3 months of double-blind study</td>
<td>1: Registered after enrollment was complete</td>
<td>1: Registered after enrollment was complete</td>
<td>1: Registered after enrollment was complete</td>
<td>1: Registered after enrollment was complete</td>
</tr>
</tbody>
</table>

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

- Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.
- Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); 5. Other.
- Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.
- Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.

Table 5. Study Design and Conduct Limitations: Randomized Controlled Trials of Deep Brain Stimulation for Primary Dystonia

<table>
<thead>
<tr>
<th>Study</th>
<th>Allocation</th>
<th>Blinding</th>
<th>Selective Reporting</th>
<th>Data Completeness</th>
<th>Power</th>
<th>Statistical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kupsch et al (2006)</td>
<td>1: Registered after enrollment was complete</td>
<td>1.3: Treating physicians not blinded. Primary outcome assessors blinded but secondary outcomes subject to bias</td>
<td>1. Registered after enrollment was complete</td>
<td>1: Registered after enrollment was complete</td>
<td>1: Registered after enrollment was complete</td>
<td>1: Registered after enrollment was complete</td>
</tr>
<tr>
<td>Volkman et al (2014)</td>
<td>1.3: Treating physicians not blinded. Primary outcome assessors blinded but secondary outcomes subject to bias</td>
<td>1. Registered after enrollment was complete</td>
<td>1: Registered after enrollment was complete</td>
<td>1: Registered after enrollment was complete</td>
<td>1: Registered after enrollment was complete</td>
<td>1: Registered after enrollment was complete</td>
</tr>
</tbody>
</table>

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.
Section Summary: Primary Dystonia
A review prepared for the FDA and systematic reviews have evaluated evidence on deep brain stimulation for primary dystonia. There are numerous case series and 2 RCTs. Both RCTs found that severity scores improved more after active than after sham stimulation. A pooled analysis of 24 studies, mainly uncontrolled, found improvements in motor scores and disability scores after 6 months and at last follow-up (mean, 32 months).

Tardive Dyskinesia and Tardive Dystonia
Clinical Context and Therapy Purpose
The purpose of deep brain stimulation is to provide a treatment option that is an alternative to or an improvement on existing therapies for individuals with tardive dyskinesia and tardive dystonia.

The following PICO was used to select literature to inform this review.

**Populations**
The relevant population of interest are individuals with tardive dyskinesia and tardive dystonia.

**Interventions**
The therapy being considered is deep brain stimulation.

**Comparators**
The following practice is currently being used to treat primary dystonia: pharmacologic therapy.

**Outcomes**
The general outcomes of interest are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Follow-up in studies has been up to 4 years.

**Study Selection Criteria**
Methodologically credible studies were selected using the following principles:
- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

**Review of Evidence**
Systematic Review
Grabel et al (2023) conducted a systematic review and meta-analysis of pallidal deep brain stimulation for tardive dystonia (Tables 6 and 7). A total of 14 articles (observational studies,
randomized studies, or case reports) that described use of deep brain stimulation to the globus pallidus pars interna and assessed efficacy using the Burke-Fahn-Marsden Dystonia Rating Scale were included. There was a risk of publication bias among the included studies (p=0.009). The 134 patients ranged in age from 11 to 77 years and had a history of tardive dystonia for 0.5 to 46 years. Table 8 summarizes the results of the analysis. A mixed effects model with no covariates reported a mean improvement in dystonia score of 66.88% (95% CI, 57.46% to 68.63%). Including covariates in the model (follow-up duration, year, and baseline Burke-Fahn-Marsden Dystonia Rating Scale score) increased the estimated improvement to 72.66%. Fixed effects and random effects models had similar estimated improvement (63.1% and 70.56%, respectively).

Table 6. Comparison of Trials/Studies Included in the Systematic Review

<table>
<thead>
<tr>
<th>Study</th>
<th>Grabel et al (2023)24,</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capelle et al (2010)25, 26,</td>
<td>⚫</td>
</tr>
<tr>
<td>Chang et al (2010)26, 27, 28,</td>
<td>⚫</td>
</tr>
<tr>
<td>Franzini et al (2005)27, 28,</td>
<td>⚫</td>
</tr>
<tr>
<td>Gruber et al (2009)28, 29,</td>
<td>⚫</td>
</tr>
<tr>
<td>Katsakiori et al (2009)29,</td>
<td>⚫</td>
</tr>
<tr>
<td>Kayama et al (2021)30, 31,</td>
<td>⚫</td>
</tr>
<tr>
<td>Magarinos-Ascone et al (2008)31,</td>
<td>⚫</td>
</tr>
<tr>
<td>Sako et al (2008)32, 33, 34,</td>
<td>⚫</td>
</tr>
<tr>
<td>Shaikh et al (2015)33, 34, 35</td>
<td>⚫</td>
</tr>
<tr>
<td>Sharma et al (2019)34, 35,</td>
<td>⚫</td>
</tr>
<tr>
<td>Sobstyl et al (2016)35, 36,</td>
<td>⚫</td>
</tr>
<tr>
<td>Starr et al (2006)36, 37, 38</td>
<td>⚫</td>
</tr>
<tr>
<td>Trottenberg et al (2005)37,</td>
<td>⚫</td>
</tr>
<tr>
<td>Vidailhet et al (2005)38,</td>
<td>⚫</td>
</tr>
</tbody>
</table>

Table 7. Systematic Review Characteristics

<table>
<thead>
<tr>
<th>Study</th>
<th>Dates</th>
<th>Trials</th>
<th>Participants</th>
<th>N (Range)</th>
<th>Design</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grabel et al (2023)</td>
<td>until 2021</td>
<td>14</td>
<td>Patients who received DBS to the globus pallidus pars interna for TD</td>
<td>134 (2 to 22)</td>
<td>RCT, observational studies, and case reports</td>
<td>0.03 to 53 months</td>
</tr>
</tbody>
</table>

DBS: deep brain stimulation; RCT: randomized controlled trial; TD: tardive dystonia.

Table 8. Systematic Review Results

<table>
<thead>
<tr>
<th>Study</th>
<th>BFMDRS, mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grabel et al (2023)24,</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>134</td>
</tr>
<tr>
<td>Overall estimate of improvement, % (mixed effects model)</td>
<td>66.88 (11.96)</td>
</tr>
</tbody>
</table>

BFMDRS: Burke-Fahn-Marsden-Dystonia-Rating-Scale; CI: confidence interval; SD, standard deviation

Randomized Controlled Trials

One RCT evaluated efficacy of pallidal deep brain stimulation in patients with tardive dystonia. Characteristics are shown in Table 9 and results are in Table 10. Briefly, Gruber et al (2018) assessed dystonia/dyskinesia severity using the Burke-Fahn-Marsden Dystonia Rating Scale at 3 months between active versus sham deep brain stimulation.39 Twenty-five patients were randomized. In the intention-to-treat analyses, the between group difference of dystonia severity was not significant at 3 months. Adverse events occurred in 10/25 of patients; 3 of the adverse events were serious. The study was originally powered to include 48 patients, but only 25 were randomized and analyses may be underpowered. Study limitations are described in Tables 11 and 12.
Table 9. Characteristics of Randomized Controlled Trials of Deep Brain Stimulation for Tardive Dyskinesia and Tardive Dystonia

<table>
<thead>
<tr>
<th>Study, Trial</th>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gruber et al 2018 39; NCT00331669</td>
<td>Germany</td>
<td>15</td>
<td>2006 to 2009</td>
<td>Adults with tardive dystonia disease duration of at least 18 months with marked disability and deterioration of activities of daily living owing to tardive dystonia despite medical treatment</td>
<td>n=12 Active Pallidal DBS n=13 Comparator Sham</td>
</tr>
</tbody>
</table>

DBS: deep brain stimulation.

Table 10. Results of Randomized Controlled Trials of Deep Brain Stimulation for Tardive Dyskinesia and Tardive Dystonia

<table>
<thead>
<tr>
<th>Study</th>
<th>Dystonia severity</th>
<th>Disability</th>
<th>Quality of life</th>
<th>Depression symptoms</th>
<th>Serious Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gruber et al 2018 39.</td>
<td>Change in BFMDRS Movement score at 3 months, Mean (SD)</td>
<td>Change in BFMDRS Disability score at 3 months, Mean (SD)</td>
<td>Change in SF-36 at 3 months, Mean (SD)</td>
<td>HAM-D at 3 months, Mean (SD)</td>
<td>3 events (episodes of confusion, worsening of dystonia following gastrointestinal infection, skin erosion)</td>
</tr>
<tr>
<td>N</td>
<td>25</td>
<td>25</td>
<td>24</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>DBS</td>
<td>-5.6 (9.1)</td>
<td>0.5 (5.5)</td>
<td>PCS: 5.4 (10.0); MCS: 0.5 (10.9)</td>
<td>1.4 (5.5)</td>
<td></td>
</tr>
<tr>
<td>Sham</td>
<td>-5.9 (13.9)</td>
<td>-0.3 (1.2)</td>
<td>PCS: 1.6 (7.8); MCS: -0.6 (4.8)</td>
<td>2.2 (6.6)</td>
<td></td>
</tr>
</tbody>
</table>

Treatment effect (95% CI) p=.72 p=.43 PCS: p=.17; MCS: p=.69 p=.53

BFMDRS: Burke-Fahn-Marsden-Dystonia-Rating-Scale; DBS: deep brain stimulation; HAM-D: Hamilton Depression Score; MCS Mental component score; PCS: Physical Component Score; SD: standard deviation; SF-36: short form 36 item quality of life survey.

Table 11. Study Relevance Limitations: Randomized Controlled Trials of Deep Brain Stimulation for Tardive Dyskinesia and Tardive Dystonia

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcomes</th>
<th>Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gruber et al 2018 39.</td>
<td>1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.</td>
<td>Not clearly defined; Version used unclear; Delivery not similar intensity as comparator; Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); Other.</td>
<td>Not clearly defined; Not standard or optimal; Delivery not similar intensity as intervention; Not delivered effectively; Other.</td>
<td>Key health outcomes not addressed; Physiologic measures, not validated surrogates; Incomplete reporting of harms; Not establish and validated measurements; Clinically significant difference not prespecified; Clinically significant difference not supported; Other.</td>
<td>1: 3 month follow-up in blinded period</td>
</tr>
</tbody>
</table>

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.

Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); 5. Other.

Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.


Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.
Table 12. Study Design and Conduct Limitations: Randomized Controlled Trials of Deep Brain Stimulation for Tardive Dyskinesia and Tardive Dystonia

<table>
<thead>
<tr>
<th>Study</th>
<th>Allocation</th>
<th>Blinding</th>
<th>Selective Reporting</th>
<th>Data Completeness</th>
<th>Power</th>
<th>Statistical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gruber et al 2018</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1: Study powered to include 48 patients but only 25 patients enrolled</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

- **Blinding** key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.
- **Selective Reporting** key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.
- **Data Completeness** key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).
- **Power** key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.
- **Statistical** key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

**Observational Studies**

Stimulation of the globus pallidus interna was examined as a treatment for tardive dyskinesia in a multicenter observational study by Damier et al (2007), with a double-blind evaluation at 6 months (comparison of symptoms in the on and off positions).40 The trial was stopped early due to successful treatment (>40% improvement at 6 months) in the first 10 patients. In the double-blind evaluation of these patients, stimulation was associated with a mean decrease of 50% in the symptom score when the device was on versus off.

Pouclet-Courtemanche et al (2016) reported on a case series of 19 patients with severe pharmacoresistant tardive dyskinesia treated with deep brain stimulation.41 Patients were assessed 3, 6, and 12 months after the procedure. At 6 months, all patients had experienced greater than 40% reduction in symptoms as measured on the Extrapyramidal Symptoms Rating Scale. At 12 months, the mean decrease in Extrapyramidal Symptoms Rating Scale score was 58% (range, 21% to 81%).

**Section Summary: Tardive Dyskinesia and Tardive Dystonia**

Evidence for the use of deep brain stimulation to treat tardive syndromes consists of a systematic review, an RCT with 3 months of blinded follow-up and case series with follow-up of 6 months to approximately 4 years. The systematic review found an improvement in symptom severity with deep brain stimulation, but the authors noted some cases of symptom worsening or lack of improvement. The RCT did not report statistically significant improvement in the dystonia severity outcomes or the secondary outcomes related to disability and quality of life for deep brain stimulation compared to sham, but the study did not recruit the number of patients for which it was originally powered.

**Drug-Refractory Epilepsy**

**Clinical Context and Therapy Purpose**

The purpose of deep brain stimulation is to provide a treatment option that is an alternative to or an improvement on existing therapies for individuals with drug-refractory epilepsy. Approximately one-third of patients with epilepsy do not respond to anti-epileptic drugs and are considered to have drug-resistant epilepsy. Patients with drug-resistant or refractory epilepsy have a higher risk of death as well as a high burden of epilepsy-related disabilities and limitations.
The following PICO was used to select literature to inform this review.

**Populations**
The relevant population(s) of interest are individuals with epilepsy refractory to medical treatment who are not candidates for resective surgery. The International League Against Epilepsy defined drug-resistant as failure of adequate trials of 2 tolerated, appropriately chosen and administered anti-epileptic drugs, used as monotherapy or in combination, to achieve seizure freedom. Individuals who are not candidates for resective surgery include those with multifocal seizure onset, significant medical comorbidities, or generalized-onset epilepsy.

**Interventions**
The therapy being considered is deep brain stimulation. Several areas of the brain have been targeted.

**Comparators**
The following practice is currently being used to treat drug-refractory epilepsy: pharmacologic therapy and vagus nerve stimulation. The pharmacologic treatment for chronic epilepsy consists of anti-epileptic drugs. A ketogenic diet may be used as an adjunctive treatment. For patients with epilepsy that is refractory to medical treatment, surgery options such as resection or disconnection may be considered.

Vagus nerve stimulation may also be used in patients with drug-refractory epilepsy who are not candidates for resective surgery.

Sham control may be used in RCTs.

**Outcomes**
Key efficacy outcomes include measures of seizure frequency or severity, response (reduction in seizure frequency by 50% or more), freedom from seizure, functional ability and disability, medication use, hospitalizations and quality of life. The Quality of Life Inventory in Epilepsy (QOLIE-31) is a tool used to assess the impact of antiepileptic treatment on patients’ lives; the minimally important change in patients with treatment-resistant seizures was 5 points.

Key safety outcomes include death, stroke, depression, cognition, infection and other device and procedure related events. Length of follow-up was up to 7 years.

**Study Selection Criteria**
Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

**Review of Evidence**
**Systematic Reviews**
A Cochrane systematic review on deep brain and cortical stimulation for epilepsy was published in 2017 and included RCTs published through 2016. The review included 1 trial on anterior thalamic nucleus deep brain stimulation for multifocal epilepsy (n=109, see discussion in following section), 1 trial on centromedian thalamic deep brain stimulation for multifocal or generalized epilepsy (n=7), and 3 RCTs on hippocampal deep brain stimulation for medial temporal lobe epilepsy (n=15). Meta-
analyses provided estimates by site of stimulation. The RCT using anterior thalamic nucleus deep brain stimulation will be discussed in the following section.

Two systematic reviews on the use of deep brain stimulation for drug-resistant epilepsy, both published in 2018, assessed many of the same studies.45,46 The larger review, by Li et al (2018), identified 10 RCTs and 48 uncontrolled studies.45 The literature search date was not reported. Meta-analyses were not performed. The largest RCT in which deep brain stimulation targeted the anterior nucleus of the thalamus. Fisher et al (2010)47; is described below. Reviewers concluded that more robust clinical trials would be needed.

Randomized Controlled Trials
Trials including 15 patients or more are described in more detail in this section. Study characteristics are in Table 13 and results are in Table 14. Tables 15 and 16 describe study limitations.

Fisher et al (2010) conducted a U.S. multicenter, double-blind, randomized trial, Stimulation of the Anterior Nuclei of the Thalamus for Epilepsy (SANTE).47 Included were 110 patients, ages 18 to 65 years, who experienced at least 6 partial seizures (including secondarily generalized seizures) per month, but no more than 10 per day. An additional 47 patients were enrolled in the trial but did not undergo implantation. At least 3 antiepileptic drugs must have failed to produce adequate seizure control before baseline, with 1 to 4 antiepileptic drugs used at the time of study entry. Patients were asked to keep a daily seizure diary during treatment. All patients received deep brain stimulation device implantation, with half the patients randomized to stimulation (n=54) and half to no stimulation (n=55) during a 3-month blinded phase; thereafter all patients received unblinded stimulation. Baseline monthly median seizure frequency was 19.5. During the first and second months of the blinded phase, the difference in seizure reduction between stimulation on (-42.1%) and stimulation off (-28.7%) did not differ significantly. In the last month of the blinded phase, the stimulated group had a significantly greater reduction in seizures (-40.4%) than the control group (-14.5%; p=.002; see Table 13). The publication stated that changes in additional outcome measures did not show significant treatment group differences during the double-blind phase, including 50% responder rates, Liverpool Seizure Severity Scale, QOLIE-31 scores, but data were not shown. Data for these outcomes are available in the FDA Summary of Safety and Effectiveness, see Table 13.48.

Troster et al (2017) assessed neuropsychological adverse events from the SANTE trial during the 3-month blinded phase, and at 7-year follow-up during the open-label noncomparative phase (see Table 12).49 At baseline, there were no differences in depression history between groups. During the 3-month blinded phase of the trial, depression was reported in 8 (15%) patients from the stimulation group and in 1 (2%) patient from the no stimulation group (p=.02). At the 7 year follow-up, after the treatment groups had been combined, there was no statistically significant difference in Profile of Mood State depression score compared with baseline. Memory adverse events also occurred at significantly different rates between the treatment groups during the blinded phase (7 in the active group, 1 in the control group; p=.03). At the 7 year follow-up, most cognitive function tests did not improve over baseline measurements.

Cukiert et al (2017) conducted a double-blind, placebo-controlled randomized trial evaluating 16 patients with refractory temporal lobe epilepsy (see Table 12).50 All patients underwent deep brain stimulation device implantation, and were followed for 6 months. Patients were seen weekly to receive the treatment or placebo. To maintain double-blind status, programming was performed by a nontreating assistant. Patients kept a seizure diary during the study period. Patients were considered seizure-free if no seizures occurred during the last 2 months of the trial. Responders were defined as patients experiencing a reduction of 50% or more in frequency reduction. Results are summarized in Table 12.
Table 13. Summary of Randomized Controlled Trials Characteristics for Epilepsy

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fisher et al (2010)(^a) Troster et al (2017)(^a) SANTE</td>
<td>U.S.</td>
<td>17</td>
<td>NR</td>
<td>Patients with partial seizures, including secondary generalized seizures, refractory to ≥3 medications</td>
<td>5-V stimulus intensity (n=54) No stimulation (n=55)</td>
</tr>
<tr>
<td>Cukiert et al (2017)(^a)</td>
<td>Brazil</td>
<td>1</td>
<td>2014 to 2016</td>
<td>Patients with temporal lobe epilepsy, refractory to ≥3 medications</td>
<td>Weekly 0.4-V to 2-V stimulus intensity (n=8) Weekly impedance testing, no stimulation (n=8)</td>
</tr>
</tbody>
</table>

NR: not reported; SANTE: Stimulation of the Anterior Nuclei of the Thalamus for Epilepsy; V: volts.

Table 14. Summary of Randomized Controlled Trials Outcomes for Epilepsy

<table>
<thead>
<tr>
<th>Study</th>
<th>Seizure Reduction, % (p)</th>
<th>Responder (50% or more reduction in seizure frequency)</th>
<th>Hospitalizations</th>
<th>Seizure severity</th>
<th>Quality of life</th>
<th>Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 Month</td>
<td>2 Months</td>
<td>3 Months</td>
<td>Mean (SD)</td>
<td>Change (SD)</td>
<td>Change (SD)</td>
</tr>
<tr>
<td>Fisher et al (2010)(^a) Troster et al (2017)(^a) SANTE</td>
<td>DBS</td>
<td>30%(^a)</td>
<td>0.08 (0.56)(^a)</td>
<td>22%(^a)</td>
<td>-8.2 (17.8)(^a)</td>
<td>2.5 (8.7)(^a)</td>
</tr>
<tr>
<td></td>
<td>Sham</td>
<td>26%(^a)</td>
<td>0.37 (1.17)(^a)</td>
<td>22%(^a)</td>
<td>-6.8 (19.6)(^a)</td>
<td>2.8 (8.0)(^a)</td>
</tr>
<tr>
<td></td>
<td>Between-group difference</td>
<td>-11% (NS)</td>
<td>-11% (NS)</td>
<td>-29% (0.002)</td>
<td>p=.83(^a)</td>
<td>p=.11(^a)</td>
</tr>
<tr>
<td></td>
<td>FIAS at 6 Months</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cukiert et al (2017)(^a)</td>
<td>Stimulation on</td>
<td>4 seizure-free; 3 responders; 1 no response</td>
<td></td>
<td></td>
<td></td>
<td>2 patients with local skin erosions at cranial site of implant, treated with antibiotics</td>
</tr>
</tbody>
</table>
Study limitations are described in Tables 15 and 16. The SANTE study included relevant patients and outcomes and had few design and conduct limitations. Both publications did not report several important outcomes such as quality of life and functional outcomes, although SANTE outcomes are available in the FDA Summary of Safety and Effectiveness. Cukiert et al (2017) did not include information on power/sample size, flow of participants, and missing data.

Table 15. Study Relevance Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcomes</th>
<th>Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fisher et al (2010)(^a)(^b); SANTE</td>
<td>47, SANTE</td>
<td>1: Responder and freedom from seizure, quality of life outcomes not reported in publication; reported in SSED.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cukiert et al (2017)(^a)(^b)</td>
<td>50, SANTE</td>
<td>1: Quality of life and functional outcomes not reported</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SANTE: Stimulation of the Anterior Nuclei of the Thalamus for Epilepsy; SSED: Summary of Safety and Effectiveness.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

\(^a\) Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.

\(^b\) Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); 5. Other.

\(^c\) Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.

\(^d\) Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. Incomplete reporting of harms; 4. Not establish and validated measurements; 5. Clinically significant difference not prespecified; 6. Clinically significant difference not supported; 7. Other.

\(^e\) Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.

Table 16. Study Design and Conduct Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Allocation</th>
<th>Blinding</th>
<th>Selective Reporting</th>
<th>Data Completeness</th>
<th>Power</th>
<th>Statistical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fisher et al (2010)(^a)(^b); SANTE</td>
<td>2: Several seizure outcomes as well as quality of life collected but not reported in publication; available in SSED.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Cukiert et al (2017)\(^{50}\).

- Allocation: 2: No mention of how missing diary data or other missing data were handled in analysis. No flow of participants described.
- Blinding: 1: No power calculations
- Selective Reporting: 2: Not clear if analyses were done independently for each time point or if analyses adjusted for multiple observations
- Data Completeness: 4: Comparative treatment effects not calculated
- Power: 1: No power calculations
- Statistical: 2: Not clear if analyses were done independently for each time point or if analyses adjusted for multiple observations

SANTE: Stimulation of the Anterior Nuclei of the Thalamus for Epilepsy; SSED: Summary of Safety and Effectiveness.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

- Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).
- Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.
- Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

Observational Studies

Long-term outcomes of the SANTE trial were reported by Salanova et al (2015).\(^{51}\) The uncontrolled open-label portion of the trial began after 3 months, and beginning at 13 months stimulation parameters could be adjusted at the clinician’s discretion. Of the 110 implanted patients, 105 (95%) completed the 13-month follow-up, 98 (89%) completed the 3-year follow-up, and 83 (75%) completed 5 years. Among patients with at least 70 days of diary entries, the median change in seizure frequency from baseline was 41% at 1 year and 69% at 5 years (\(p<.001\) for both). During the trial, 39 (35%) of 110 patients had a device-related serious adverse event, most of which occurred in the first months after implantation. They included implant-site infection (10% of patients) and lead(s) not within target (8.2% of patients). Seven deaths occurred during the trial and none were considered to be device-related. Depression was reported in 41 (37%) patients following implant; in 3 cases, it was considered device-related. Memory impairment (nonserious) was reported in 30 (27%) patients during the trial, half of whom had a history of the condition.

A 7 year follow-up of SANTE was reported in the FDA Summary of Safety and Effectiveness (Table 17 ).\(^{48}\). Seventy-three (66% of implanted) patients completed the year 7 visit. Reasons for withdrawals from the study after implantation were: death (6), withdrawal of consent (5), investigator decision (3), therapeutic product ineffective (13), implant site infection or pain (6), other adverse event (7), and elective device removal (1). Fifty patients were included in the year 7 analysis of responder rate; see Table 13. Seventy-four percent of the 50 patients were responders (50% or greater reduction in seizure frequency). At year 7, QOLIE-31 scores (\(n=67\)) improved by a mean of 4.9 (SD, 11) points. Liverpool Seizure Severity Scale scores (\(n=67\)) improved by a mean of 18 points (SD, 23) at year 7. As the FDA documentation notes, interpretation of the long-term follow-up is limited by several factors: patients were aware they were receiving deep brain stimulation, only 66% of implanted patients completed the year 7 visit and those who did not do well may be more likely to leave the study, and changes in anti-epileptic drugs were allowed in long-term follow-up.
Table 17. 7-Year Outcomes from SANTE

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Median seizure frequency (change from BL)</th>
<th>Responders (≥50% reduction in seizure frequency)</th>
<th>LSSS, Mean (SD)</th>
<th>QOLIE-31, ≥5 point improvement</th>
<th>Hospitalizations, mean (SD) annual number of hospitalizations per patients</th>
<th>Serious device-related adverse event</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>50</td>
<td>50</td>
<td>67</td>
<td>67</td>
<td>80</td>
<td>110</td>
</tr>
<tr>
<td>Estimate</td>
<td>-75%&lt;sup&gt;b&lt;/sup&gt;</td>
<td>74%</td>
<td>-18.1 (23.5)</td>
<td>43%</td>
<td>0.08 (0.28)</td>
<td>34.5%</td>
</tr>
</tbody>
</table>

BL: baseline; LSSS: Liverpool Seizure Severity Scale; QOLIE-31: Quality of Life in Epilepsy Score; SD: standard deviation; SANTE: Stimulation of the Anterior Nuclei of the Thalamus for Epilepsy.

<sup>a</sup> 110 patients were implanted with DBS in SANTE

<sup>b</sup> -39% assuming worst case for missing data.

Kim et al (2017) conducted a retrospective chart review of 29 patients with refractory epilepsy treated with deep brain stimulation. Patients’ mean age was 31 years, they had had epilepsy for a mean of 19 years, and had a mean preoperative frequency of tonic-clonic seizures of 27 per month. Mean follow-up was 6.3 years. Median seizure reduction from baseline was 71% at year 1, 74% at year 2, and ranged from 62% to 80% through 11 years of follow-up. Complications included 1 symptomatic intracranial hemorrhage, 1 infection requiring removal and reimplantation, and 2 lead disconnections.

**Section Summary: Drug-Refractory Epilepsy**

A systematic review identified several RCTs and many observational studies in which deep brain stimulation was evaluated for the treatment of epilepsy. Many different targets have been investigated, and most of the RCTs included fewer than 15 patients. The largest RCT consisted of a 3 month blinded phase in which patients were randomized to stimulation or no stimulation targeting the anterior nucleus of the thalamus. After the randomized phase, all patients received stimulation and were followed for 13 additional months. Findings in the first 3 months were mixed: patients reported significantly fewer seizures in the third month but not in the first or second month. There were no differences between groups in 50% responder rates, Liverpool Seizure Severity Scale, or QOLIE-31 scores. In the uncontrolled follow-up period of the RCT and in multiple observational studies, patients reported fewer seizures compared with baseline; however, without a control group, interpretation of results is limited. In addition interpretation of 7 year follow-up of SANTE is limited by high loss to follow-up. Serious adverse events were reported in about one-third of patients. The risk-benefit ratio is uncertain. Deep brain stimulation has not been directly compared to vagus nerve stimulation, another treatment used in patients with drug-refractory epilepsy who are not candidates for resective surgery.

**Tourette Syndrome**

**Clinical Context and Therapy Purpose**

The purpose of deep brain stimulation is to provide a treatment option that is an alternative to or an improvement on existing therapies for patients with Tourette syndrome. Tourette syndrome is a neurological disorder marked by multiple motor and phonic tics with onset during childhood or early adulthood and which often improve in adulthood. Children with Tourette syndrome frequently have other comorbid conditions such as attention deficit hyperactivity disorder or obsessive-compulsive disorder (OCD).

The following PICO was used to select literature to inform this review.

**Populations**

The population of interest are individuals with Tourette syndrome who have disabling tics that are refractory to optimal medical management.
Interventions
The therapy being considered is deep brain stimulation. Several targets have been investigated such as the medial thalamus at the crosspoint of the centromedian nucleus, substantia periventricularis, and nucleus ventro-oralisinternus, subthalamic nucleus, caudate nucleus, globus pallidus interna, and the anterior limb of the internal capsule and nucleus accumbens.

Comparators
The following practice is currently being used to treat Tourette syndrome: pharmacologic therapy and cognitive-behavioral therapy. Intervention may be initiated when symptoms of Tourette syndrome are disabling or cause difficulty in functioning. Individuals may require a therapy to treat tics, as well as comorbid attention deficit hyperactivity disorder or OCD. Medication treatment for tics might include antidopaminergic drugs, alpha adrenergic agonists drugs, topiramate, or injections of botulinum toxin. Behavioral therapy, primarily based on habit reversal therapy is also used.

Outcomes
Key efficacy outcomes include measures of motor impairment, tic severity (Yale Global Tic Severity Scale [YGTSS]), functional ability and disability, medication use, and quality of life. The overall score for the Yale Global Tic Severity Scale is on a scale from 0 to 100, with lower scores indicating less severe symptoms. It has a motor tic and verbal tick subscale.

Key safety outcomes include death, stroke, depression, cognition, infection, and other device and procedure related events.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Review of Evidence
Systematic Reviews
Several systematic reviews of the literature on deep brain stimulation for Tourette syndrome have been published. Most recent systematic reviews (i.e., those published in 2015 to 2017) qualitatively described the literature.

Baldermann et al (2016) conducted pooled analyses of study data. That review identified 57 studies on deep brain stimulation for Tourette syndrome, 4 of which were randomized crossover studies. The studies included a total of 156 cases. Twenty–four studies included a single patient and 4 had sample sizes of 10 or more (maximum, 18 patients). Half of the patients (n=78) received thalamus stimulation, and the next most common areas of stimulation were the globus pallidus interna anteromedial part (n=44) and post ventrolateral part (n=20). Two of the RCTs used thalamic stimulation, 1 used bilateral globus pallidus stimulation, and 1 used both. The primary outcome was the YGTSS. In a pooled analysis of within-subject pre-post data, there was a median improvement of 53% in YGTSS score, a decline from a median score of 83 to 35 at last follow-up. Moreover, 81% of patients showed at least a 25% reduction in YGTSS score and 54% showed improvements of 50% or more. In addition, data were pooled from the 4 crossover RCTs: 27 patients received deep brain stimulation and 27 received a control intervention. Targets included the thalamus and the globus pallidus. In the pooled analysis, there was a statistically significant between-group difference, favoring deep brain stimulation (standard MD, 0.96; 95% CI, 0.36 to 1.56). Reviewers noted that the effect size of 0.96 would be considered large.
Wehmeyer et al (2021) also conducted a pooled analysis. A total of 65 studies with 376 patients were included; the primary outcome was YGTSS scores and scores were significantly reduced at maximum follow-up of median 25 months (p<.001). The median scores decreased from 79.92 points (interquartile range [IQR], 13.25) to 34.69 points (IQR, 20.93) post-surgery, which represented a reduction rate of 56.59%. A majority of patients (69.4%) also experienced symptom reduction of more than 50% at maximum follow-up. In addition, other tic-related outcome measures (modified Rush video-based tic rating scale, YGTSS total tic score) and comorbidities (Yale-Brown Obsessive Compulsive Scale, Becks Depression Inventory), were also significantly reduced after deep brain stimulation.

**Randomized Controlled Trials**

Trials including 15 patients or more will be described in more detail in this section. Study characteristics are shown in Table 18 and results are shown in Table 19. Study limitations are described in Tables 20 and 21.

The crossover RCT was published by Kefalopoulou et al (2015). The double-blind trial included 15 patients with severe medically refractory Tourette syndrome; all received bilateral globus pallidus interna surgery for deep brain stimulation and were randomized to the off-stimulation phase first or the on-stimulation phase first for 3 months, followed by the opposite phase for the next 3 months. Of the 15 receiving surgery, 14 were randomized and 13 completed assessments after both on and off phases. For the 13 trial completers, mean Yale Global Tic Severity Scale scores were 80.7 in the off-stimulation phase and 68.3 in the on-stimulation phase. The mean difference in Yale Global Tic Severity Scale scores indicated an improvement of 12.4 points (95% CI, 0.1 to 24.7 points), which was statistically significant (p=.048) after Bonferroni correction. There was no significant between-group difference in Yale Global Tic Severity Scale scores for patients randomized to the on-stimulation phase first or second. Three serious adverse events were reported, 2 related to surgery and 1 related to stimulation.

Welter et al (2017) reported results of a sham-controlled RCT of 3 months of anterior globus pallidus interna deep brain stimulation in 17 adults with severe Tourette Syndrome. The primary endpoint was difference in YGTSS score between the beginning and end of the 3 month double-blind period. The study was powered to detect a benefit amounting to a 30-point reduction in YGTSS score in the active deep brain stimulation group and may, therefore, have been underpowered to detect smaller changes in YGTSS. There was no significant differences in YGTSS score change between groups (active deep brain stimulation median change, 1.1% [IQR, −23.9 to 38.1] vs. sham deep brain stimulation median change, 0.0% [IQR, −10.6 to 4.8]; p=.39). There was also no difference between groups in change in co-morbid symptoms of OCD or depression or quality of life. There were 15 serious adverse events in 13 patients including: infections in 4 patients, 1 electrode misplacement, 1 episode of depressive signs, and 3 episodes of increased tic severity and anxiety.

**Table 18. Characteristics of Randomized Controlled Trials of Deep Brain Stimulation for Tourette Syndrome**

<table>
<thead>
<tr>
<th>Study, Trial</th>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kefalopoulou et al (2015)59; NCT01647269</td>
<td>United Kingdom 2</td>
<td>2009 to 2013</td>
<td>Adults with Tourette syndrome with chronic and severe tic, with severe functional impairment (12+ months), had not responded to conventional medical treatment, behavioral intervention had been thought inappropriate</td>
<td>Stimulation on (Bilateral globus pallidus interna DBS) Stimulation off</td>
<td></td>
</tr>
</tbody>
</table>

Reproduction without authorization from Blue Shield of California is prohibited
### Study; Trial

<table>
<thead>
<tr>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>France</td>
<td>8</td>
<td>2007 to 2012</td>
<td>n=8 anterior internal globus pallidus DBS</td>
<td>n=9 Sham DBS</td>
</tr>
</tbody>
</table>

or had been unsuccessful

Welter et al (2017) 
NCT00478842

| DBS: deep brain stimulation. |

#### Table 19. Results of Randomized Controlled Trials of Deep Brain Stimulation for Tourette Syndrome

<table>
<thead>
<tr>
<th>Study</th>
<th>Tic severity</th>
<th>Co-morbid symptoms</th>
<th>Quality of life</th>
<th>Depression symptoms</th>
<th>Serious Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kefalopoulou et al (2015)</td>
<td>YGTSS, Mean (SD) at 3 months</td>
<td>Y-BOCS, Mean (SD) at 3 months</td>
<td>GTS-QOL, Mean (SD) at 3 months</td>
<td>Beck Depression Inventory, Mean (SD) at 3 months</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>15(^a)</td>
<td>15(^a)</td>
<td>15(^a)</td>
<td>15(^a)</td>
<td>15(^a)</td>
</tr>
<tr>
<td>DBS</td>
<td>68.3 (18.6)</td>
<td>12.8 (10.0)</td>
<td>54.3 (28.4)</td>
<td>21.0 (13.8)</td>
<td>3 (20%)</td>
</tr>
<tr>
<td>No stimulation</td>
<td>80.7 (12.0)</td>
<td>14.6 (10.3)</td>
<td>62.0 (24.7)</td>
<td>20.5 (14.3)</td>
<td></td>
</tr>
<tr>
<td>Treatment effect (95% CI)</td>
<td>12.4 (0.1–24.7, p=.05)</td>
<td>p=.98</td>
<td>p=.04</td>
<td>p=.13</td>
<td></td>
</tr>
<tr>
<td>Welter et al (2017)</td>
<td>YGTSS, Mean change (CI) at 3 months</td>
<td>Y-BOCS, Mean change (CI) at 3 months</td>
<td>SF-36, Mean change (CI) at 3 months</td>
<td>MADRS, Mean change at 3 months</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>16</td>
<td>16</td>
<td>16</td>
<td>16</td>
<td>19</td>
</tr>
<tr>
<td>DBS</td>
<td>-4.5 (-12.5 to 0.5)</td>
<td>-3.5 (-6.8 to 0.3)</td>
<td>6.1 (1.2 to 8.7)</td>
<td>-2.0 (-6.0 to 0.5)</td>
<td>15 serious adverse events (3 in patients who withdrew before stimulation and 6 each in the active and sham stimulation groups) occurred in 13 patients: infections in 4 patients, 1 electrode misplacement, 1 episode of depressive signs, and 3 episodes of increased tic severity and anxiety</td>
</tr>
</tbody>
</table>

### Notes:
- CI: confidence interval; DBS: deep brain stimulation; GTS-QOL: Gilles de la Tourette Syndrome Quality of Life scale; MADRS: Montgomery and Asberg Rating Scale; MCS: Mental Component Score; PCS: Physical component Score; RCT: randomized controlled trial; SD: standard deviation; SF-36: Short-Form 36 Item Quality of Life Survey; Y-BOCS: Yale and Brown Obsessive Compulsive Scale; YGTSS: Yale Global Tic Severity Scale.
- \(^a\) Crossover design
Table 20. Study Relevance Limitations: Randomized Controlled Trials of Deep Brain Stimulation for Tourette Syndrome

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcomes</th>
<th>Follow-Up*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kefalopoulou et al (2015)⁶⁹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1. 3 months of follow-up</td>
</tr>
<tr>
<td>Welter et al (2017)⁶⁰</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1. 3 months of follow-up</td>
</tr>
</tbody>
</table>

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<table>
<thead>
<tr>
<th>Limitation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.</td>
</tr>
<tr>
<td>Intervention</td>
<td>1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); 5. Other.</td>
</tr>
<tr>
<td>Comparator</td>
<td>1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.</td>
</tr>
<tr>
<td>Follow-Up</td>
<td>1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.</td>
</tr>
</tbody>
</table>

Table 21. Study Design and Conduct Limitations: Randomized Controlled Trials of Deep Brain Stimulation for Tourette Syndrome

<table>
<thead>
<tr>
<th>Study</th>
<th>Allocation</th>
<th>Blinding</th>
<th>Selective Reporting</th>
<th>Data Completeness</th>
<th>Power</th>
<th>Statistical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welter et al (2017)⁶⁰</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3. Powered to detect a 30 point reduction in YGTSS in active DBS group</td>
<td></td>
</tr>
</tbody>
</table>

DBS: deep brain stimulation; YGTSS: Yale Global Tic Severity Scale.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<table>
<thead>
<tr>
<th>Limitation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data Completeness</td>
<td>1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).</td>
</tr>
<tr>
<td>Power</td>
<td>1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.</td>
</tr>
<tr>
<td>Statistical</td>
<td>1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.</td>
</tr>
</tbody>
</table>

Observational Studies

Martinez-Ramirez et al (2018) reported prospective data from the International Deep Brain Stimulation Database and Registry including 185 consecutive patients with refractory Tourette syndrome who were treated with deep brain stimulation between 2012 and 2016 at 31 sites in 10 countries in Australia, Europe, Asia, and North America. Sixty-four percent of the patients had comorbid OCD and 28% had comorbid attention deficit hyperactivity disorder. The population was 78% male. The mean age at diagnosis was 12 years, and mean age at surgery was 29 years. Fifty-
seven percent received deep brain stimulation in the centromedian thalamic region, 25% in the anterior internal globus pallidus, 15% in the posterior globus pallidus interna and 3% in the anterior limb of the internal capsule. The YGTSS score improved from a mean (SD) of 75 (18) at baseline to 41 (20) after 1 year of deep brain stimulation. More than one-third (35%) of patients had adverse events. Two patients (1.3%) suffered intracranial hemorrhage, 4 (3.2%) had infections, and 1 (0.6%) had lead explantation.\footnote{61}

**Section Summary: Tourette Syndrome**
A number of uncontrolled studies, RCTs, and several systematic reviews have been published. Most studies, including the RCTs, had sample sizes less than 15 patients and used a variety of deep brain stimulation targets. Two RCTs with 15 or more patients have been reported. One RCT found differences in severity of Tourette syndrome for active versus sham at 3 months, while the other RCT did not. Neither study demonstrated improvements in comorbid symptoms of OCD or depression. Both studies reported high rates of serious adverse events.

**Cluster Headache and Facial Pain**

**Clinical Context and Therapy Purpose**
The purpose of deep brain stimulation is to provide a treatment option that is an alternative to or an improvement on existing therapies for individuals with cluster headache or facial pain. Deep brain stimulation of the posterior hypothalamus for the treatment of chronic cluster headaches has been investigated, because functional studies have suggested cluster headaches have a central hypothalamic pathogenesis.

The following PICO was used to select literature to inform this review.

**Populations**
The relevant population of interest are individuals with cluster headache or facial pain. The International Headache Society’s International Classification of Headache Disorders classifies types of primary and secondary headaches.\footnote{62} A summary of cluster headache based on the International Classification of Headache Disorders criteria is below.

Cluster headaches are primary headaches classified as trigeminal autonomic cephalalgias that can be either episodic or chronic. The diagnostic criteria for cluster headaches states that these are attacks of severe, unilateral orbital, supraorbital, and/or temporal pain that last 15 to 180 minutes and occur from once every other day to 8 times a day. The definition further requires for the patient to have had at least 5 such attacks with at least 1 of the following symptoms or signs ipsilateral to the headache: conjunctival injection and/or lacrimation; nasal congestion and/or rhinorrhea; eyelid edema; forehead and facial sweating; miosis and/or ptosis; or a sense of restlessness or agitation. The diagnostic criteria for episodic cluster headache requires at least 2 cluster periods lasting from 7 days to 1 year if untreated, and separated by pain-free remission periods of ≥3 months. The diagnostic criteria for chronic cluster headache requires cluster headaches occurring for 1 year or more without remission, or with remission of less than 3 months. The age at onset for cluster headaches is generally 20 to 40 years, and men are affected 3 times more often than women.

**Interventions**
The therapy being considered is deep brain stimulation.

**Comparators**
The following practice is currently being used to treat cluster headache and facial pain: pharmacologic therapy, botulinum toxin, or conservative therapy (e.g., diet, exercise). The standard of care treatment to stop or prevent attacks of cluster headache or migraine is medical therapy. Guideline-recommended treatments for acute cluster headache attacks include oxygen inhalation and triptans (e.g., sumatriptan and zolmitriptan). Oxygen is preferred first-line, if available, because there are no documented adverse effects for most adults. Triptans have been associated with
primarily nonserious adverse events; some patients experience nonischemic chest pain and distal paresthesia. Use of oxygen may be limited by practical considerations, and the FDA approved labeling for subcutaneous sumatriptan limits use to 2 doses per day. Steroids injections may be used to prevent or reduce the frequency of cluster headaches. Verapamil is also frequently used for prophylaxis although the best evidence supporting its effectiveness is a placebo-controlled RCT including 30 patients.

Given the high placebo response rate in cluster headache, trials with sham deep brain stimulation are most relevant.

**Outcomes**
The general outcomes of interest are headache intensity and frequency, the effect on function and quality of life, and adverse events.

The most common outcome measures for prevention of cluster headache are decrease in headache days per month compared with baseline and the proportion of responders to the treatment, defined as those patients who report more than a 50%, 75%, or 100% decrease in headache days per month compared to pre-treatment.

Key safety outcomes include death, stroke, depression, cognition, infection, and other device and procedure related events.

**Study Selection Criteria**
Methodologically credible studies were selected using the following principles:
- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

**Review of Evidence**

**Randomized Controlled Trials**
Fontaine et al (2010) published the results of a prospective crossover, double-blind, multicenter trial in 11 patients who received deep brain stimulation of the posterior hypothalamus for severe, refractory, chronic cluster headache. The randomized phase compared active with sham stimulation during 1 month periods and was followed by a 1 year open phase. Severity of cluster headache was assessed using the weekly attack frequency (primary outcome), pain intensity, sumatriptan injections, emotional impact, and quality of life (12-Item Short-Form Health Survey). During the randomized phase, no significant changes in primary or secondary outcome measures were observed between active and sham stimulation. At the end of the open phase, 6 of 11 patients reported greater than 50% reduction in the weekly frequency of attacks.

**Observational Studies**
Another research group from Europe published 2 case series (potentially overlapping) on use of deep brain stimulation for the ipsilateral posterior hypothalamus in patients with chronic cluster headache. Stimulation was reported to result in long-term pain relief (1 to 26 months of follow-up) without significant adverse events in 16 patients with chronic cluster headaches and in 1 patient with neuralgiform headache; treatment failed in the 3 patients who had atypical facial pain.

**Section Summary: Cluster Headache and Facial Pain**
Several case series and a crossover RCT have been published on use of deep brain stimulation for cluster headache or facial pain. The RCT included 11 patients; there were no significant differences
between groups receiving active and sham stimulation. Additional RCTs or controlled studies are needed.

**Treatment-Resistant Depression**

**Clinical Context and Therapy Purpose**

The role of deep brain stimulation in treatment of other treatment-resistant depression, is also being investigated. Standard treatment modalities for treatment-resistant depression include psychotherapy, medication, and electroconvulsive therapy (ECT). However, even with a number of therapies being available, many individuals can still remain symptomatic despite treatment. As an alternative therapy option, there have been multiple trials exploring deep brain stimulation in various cerebral targets for treatment-resistant depression.

The following PICO was used to select literature to inform this review.

**Populations**
The population of interest are individuals with treatment-resistant depression.

**Interventions**
The therapy being considered is deep brain stimulation. Several targets have been investigated. Affective limbic structures include the ventral striatum/ventral capsule, anterior limb of the internal capsule, and subgenual cingulate cortex. Memory implicated structures include the fornix and nucleus basalis.

**Comparators**
Alternative treatments vary and generally include pharmacologic therapy, behavioral therapy, and psychotherapy. Sham deep brain stimulation is an appropriate comparator for RCTs.

**Outcomes**
Key efficacy outcomes include measures of symptoms severity, functional ability and disability, and quality of life.

Outcomes for major depressive disorder are measured with validated scales, most commonly the Hamilton Depression Rating or the Montgomery-Asberg Depression Rating Scale. Response is considered a 50% or greater reduction in symptoms, while remission is based on achieving a specific threshold on one of the scales.

Key safety outcomes include death, stroke, depression, cognition, infection, and other device and procedure related events.

**Study Selection Criteria**
Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.
Review of Evidence

Treatmen t-Resistant Depression

Systematic Reviews

A variety of target areas are being investigated for use of deep brain stimulation for treatment-resistant depression. Sobstyl et al (2022) published a systematic review of studies that evaluated deep brain stimulation to the subcallosal cingulate cortex in patients with treatment resistant depression.66 All study designs were considered but at least 5 patients were required and follow-up had to be a minimum of 6 months. Among the 14 studies included in the analysis (N=230), mean follow-up was 14 months (range, 6 to 24). Outcomes of interest included response and remission rates at the last follow-up visit. Using raw scores, the response rate at last follow-up was 0.57 (95% CI, 0.44 to 0.69; p=.299; \( I^2=60.76\% \)) and remission rate was 0.399 (95% CI, 0.2923 to 0.5158; p=.09; \( I^2=42.80\% \)).

Hitti et al (2020) conducted a meta-analysis and meta-regression of blinded studies that compared active deep brain stimulation to sham stimulation (12 trials, 186 patients).67 Anatomic targets included the ventral anterior limb of the internal capsule, ventral capsule/ventral striatum, subcallosal cingulate, inferior thalamic peduncle, medial forebrain bundle, and lateral habenula. The most common target was the subcallosal cingulate. Meta-analysis showed a modest reduction in depression rating scales (standardized MD, -0.75; 95% CI, -1.13 to -0.36; p<.001) with moderate heterogeneity across studies (\( I^2=59\% \)). Meta-regression did not identify a significant difference between target areas. Adverse events included headache (26% of patients), visual disturbances (21%), worsening depression (16%), sleep disturbance (16%), and anxiety (14%).

Wu et al (2021) also conducted a meta-analysis of blinded studies that compared deep brain stimulation to control (placebo or sham stimulation).68 There were 17 studies included, with a total of 233 patients; however, the majority were open-label studies (n=15). Anatomic targets included subcallosal cingulate gyrus (n=8), ventral capsule/ventral striatum (n=2), epidural prefrontal cortical (n=3), nucleus accumbens (n=1), superior lateral branch of the medial forebrain bundle (n=2), posterior gyrus rectus (n=1) and ventral anterior limb of the interna capsule (n=1). The pooled response rate estimate for the 2 RCTs was 1.45 (95% CI, 0.50 to 4.21) and for the open-label studies it was 0.56 (95% CI, 0.43 to 0.69); there was significant heterogeneity (\( I^2=73.6\% ; p<.0001 \)). The pooled estimate for remission rate in the open-label studies was 0.32 (95% CI, 0.25 to 0.39) with no statistical heterogeneity (\( I^2=30.3\% ; p=.127 \)); the pooled estimate for adverse events in the open-label studies was 0.67 (95% CI, 0.54 to 0.80) with significant heterogeneity (\( I^2=76.8\% ; p<.0001 \)).

Controlled Trials

Ventral Capsule/Ventral Striatum

One of the studies included in the meta-analysis by Hitti et al was an industry-sponsored, double-blind RCT evaluating deep brain stimulation targeting the ventral capsule/ventral striatum in patients with chronic treatment-resistant depression was published by Dougherty et al (2015).69 The trial included 30 patients with a major depressive episode lasting at least 2 years and inadequate response to at least 4 trials of antidepressant therapy. Participants were randomized to 16 weeks of active (n=16) or to sham (n=14) deep brain stimulation, followed by an open-label continuation phase. One patient, who was assigned to active treatment, dropped out during the blinded treatment phase. The primary outcome was clinical response at 16 weeks, defined as 50% or more improvement from baseline on Montgomery-Asberg Depression Rating Scale score. A response was identified in 3 (20%) of 15 patients in the active treatment group and in 2 (14%) of 14 patients in the sham control group (p=.53). During the blinded treatment phase, psychiatric adverse events occurring more frequently in the active treatment group included worsening depression, insomnia, irritability, suicidal ideation, hypomania, disinhibition, and mania. Psychiatric adverse events occurring more frequently in the sham control group were early morning awakening and purging. Findings of this trial did not support a conclusion that deep brain stimulation of the ventral capsule/ventral striatum is effective for treating treatment-resistant depression.
Anterior Limb of the Internal Capsule

Another study included in the meta-analysis by Hitti et al was a crossover RCT evaluating active and sham phases of deep brain stimulation of the ventral anterior limb of the internal capsule in 25 patients with treatment-resistant depression. Prior to the randomized phase, all patients received 52 weeks of open-label deep brain stimulation treatment with optimization of settings. Optimization ended when patients achieved a stable response of at least 4 weeks or after the 52-week period ended. At the end of the open-label phase, 10 (40%) patients were classified as responders (≥50% decrease in the Hamilton Depression Rating score) and 15 (60%) patients were classified as nonresponders. After the 52 weeks of open-label treatment, patients underwent 6 weeks of double-blind active and sham stimulation. Sixteen (64%) of 25 enrolled patients participated in the randomized phase (9 responders, 7 nonresponders). Nine patients were prematurely crossed over to the other intervention. Among all 16 randomized patients, Hamilton Depression Rating scores were significantly improved at the end of the active stimulation phase (mean Hamilton Depression Rating score, 16.5) compared with the sham stimulation phase (mean Hamilton Depression Rating score, 23.1; p<.001). Mean Hamilton Depression Rating scores were similar after the active (19.0) and sham phases for initial nonresponders (23.0). Among initial responders, the mean Hamilton Depression Rating score was 9.4 after active stimulation and 23 after sham stimulation. Trial limitations included limited sample size in the randomized phase and potential bias from having an initial year of open-label treatment; patients who had already responded to deep brain stimulation over a year of treatment were those likely to respond to active than sham stimulation in the double-blind randomized phase; and findings might not be generalizable to patients with treatment-resistant depression who are deep brain stimulation-naive.

Subcallosal Cingulate

Not included in the meta-analysis was a study by Crowell et al (2019) who reported long-term follow-up of a within-subject trial with 28 participants with treatment-resistant depression or bi-polar I disorder who were treated with deep brain stimulation of the subcallosal cingulate. Patients were included who had depression for at least 12 months with non-response to at least 3 antidepressant medications, a psychotherapy trial, and electroconvulsive therapy (lifetime). Seventeen of the patients had a 1 month sham-controlled period and 11 patients had a 1 month open label period before the stimulation was turned on. Eight year follow-up was available for 14 of the 28 participants. The primary outcome measure was the Illinois Density Index, which assesses the longitudinal area under the curve for behavioral measures; in this study these included response (≥50% decrease from baseline) and remission (score ≤7) on the Hamilton Depression Rating. More than 50% of patients maintained a response and 30% in remission, over the 8 years of follow-up. The physician-rated Clinical Global Impressions severity score improved from 6.1 (severely ill) at baseline to less than 3 (mildly ill or better) in this open label trial.

Section Summary: Treatment-Resistant Depression

Several prospective controlled trials and meta-analyses evaluating deep brain stimulation in patients with treatment resistant depression have been published. Six different target areas have been evaluated, most commonly the subcallosal cingulate. Two RCTs of deep brain stimulation in the subgenual cingulate cortex and ventral striatum/ventral capsule were terminated for futility. Another RCT of stimulation of the ventral striatum/ventral capsule did not find a statistically significant difference between groups in the primary outcome (clinical response), and adverse psychiatric events occurred more frequently in the treatment group than in the control group. More recently, a controlled crossover trial randomized patients to sham or active stimulation of the anterior limb of the internal capsule after a year of open-label stimulation. There was a greater reduction in symptom scores after active stimulation, but only in patients who were responders in the open-label phase. Deep brain stimulation for patients with major depressive disorder who have failed all other treatment options is an active area of research, but brain regions that might be effective for treatment resistant depression have yet to be established.
Obsessive-Compulsive Disorder
Clinical Context and Therapy Purpose
The role of deep brain stimulation in treatment of OCD is also being investigated. This condition can be very debilitating and cause significantly reduced quality of life for individuals. Conventional management strategies include cognitive-behavioral therapy, medications, and surgical intervention; however, response to treatment may take months, and significant improvement with these therapies is not guaranteed. Deep brain stimulation may be an alternative therapy option for individuals with treatment-refractory OCD, and some trials have explored safety and efficacy of this treatment in OCD.

The following PICO was used to select literature to inform this review.

Populations
The population of interest are individuals with OCD.

Interventions
The therapy being considered is deep brain stimulation. Several targets have been investigated. Affective limbic structures include the ventral striatum/ventral capsule, anterior limb of the internal capsule, and subgenual cingulate cortex. Memory implicated structures include the fornix and nucleus basalis.

Comparators
Alternative treatments include pharmacologic therapy, behavioral therapy, and psychotherapy. Sham deep brain stimulation is an appropriate comparator for RCTs.

Outcomes
Key efficacy outcomes include measures of symptoms severity, functional ability and disability, and quality of life.

The Yale-Brown Obsessive Compulsive Scale is a 10-item clinician-rated scale, in which higher ratings reflect more intense symptoms, and a score of 24 or more (of a possible 40) indicates severe illness. Key safety outcomes include death, stroke, depression, cognition, infection, and other device and procedure-related events.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Review of Evidence
Systematic Review
Several systematic reviews evaluating deep brain stimulation for OCD have been published.

Gadot et al (2022) published a systematic review of the efficacy of deep brain stimulation for treatment-resistant OCD and comorbid depressive symptoms. Studies were included if they reported patient-level data on the effect of deep brain stimulation on the Yale-Brown Obsessive-Compulsive Scale. Thirty-four studies (N=352) were included in the analysis (9 RCTs, 25 nonrandomized trials) and both study types had a low risk of bias. Median follow-up in the included studies was 24 months (IQR, 12 to 32). Outcomes of interest included mean difference and percent
reduction in the scale, and responder rate (defined as ≥35% reduction in Yale-Brown Obsessive-Compulsive Scale score). Random effects modeling found that Yale-Brown Obsessive-Compulsive Scale scores decreased by a mean of 47% (14.3 points; p<.01). The response rate at last follow-up was 66% (95% CI, 57% to 74%).

Mar-Barrutia et al (2021) evaluated both the short-term and long-term effects of deep brain stimulation for OCD, and included 29 studies (n=230) for short-term response and 11 studies (n=155) for long-term responses assessment; there were 7 total RCTs included. Mean follow-up duration for the short-term and long-term studies was 1.5 years and 5.3 years, respectively. The authors noted that few studies were graded as low risk of bias, and there was marked heterogeneity among the studies reviewed which makes it difficult for comparison. The primary outcome measured was the Yale-Brown Obsessive-Compulsive Scale, and the mean changes in scores from pre- to post-treatment were similar in the short-term studies (change from 33.0 to 17.2) and the long-term studies (change from 34.4 to 18.0); however, significantly more patients met criteria for response in the long-term group (70.7%) versus the short-term group (60.6%). There were 26.6% of patients in the long-term group who were classified as non-responders.

A systematic review by Raviv et al (2020) identified 28 studies that met their criteria on deep brain stimulation for OCD, including 9 RCTs, 1 cohort study, 1 case-control study, 1 cross-sectional study, and 16 case series with more than 2 patients. Only 4 studies were graded as low risk of bias, and the authors noted that there is no consensus on the optimal target. Striatal targets were the most common and included the anterior limb of the internal capsule, ventral striatum, nucleus accumbens, and caudate nucleus, but there was some discrepancy in nomenclature and overlap in stereotaxic coordinates. Additional targets included the subthalamic nucleus, bed nucleus of stria terminalis, inferior thalamic peduncle, and globus pallidus internus. The majority of studies utilized the Yale-Brown Obsessive Compulsive Scale; a score of 24 or more (of a possible 40) indicates severe illness. Responders were defined as at least 35% reduction in Yale-Brown Obsessive Compulsive Scale score and partial responders as a reduction between 25% and 35%. There was substantial variability in response for each target area, which may be related to the phenotypic diversity within the psychiatric diagnosis.

Kisely et al (2014) included only double-blind RCTs of active versus sham deep brain stimulation. Five trials (N=50 patients) met eligibility criteria and data on 44 patients were available for meta-analysis. Three were parallel-group RCTs with or without a crossover phase and 2 were only crossover trials. The site of stimulation was the anterior limb of the internal capsule (3 studies), the nucleus accumbens (1 study), and the subthalamic nucleus (1 study). Duration of treatment ranged from 2 to 12 weeks. All studies reported scores on the Yale-Brown Obsessive Compulsive Scale, and most studies designated a therapeutic response as a reduction in Yale-Brown Obsessive Compulsive Scale score of 35% or more from the pretreatment baseline, with a reduction of 25% to 35% considered a partial response. Only 1 of the 5 studies compared the proportion of responders on the Yale-Brown Obsessive Compulsive Scale as an outcome measure and that study did not find a statistically significant difference between active and sham stimulation groups. When data from the 5 studies were pooled, there was a statistically significant reduction in the mean Yale-Brown Obsessive Compulsive Scale in the active group versus the sham group (MD, -8.49; 95% CI, -12.18 to -4.80). The outcome measure, however, does not permit conclusions on whether the between-group difference is clinically meaningful. Trial authors reported 16 serious adverse events including 1 cerebral hemorrhage and 2 infections requiring electrode removal. Additionally, nonserious transient adverse events were reported, including 13 reports of hypomania, 6 of increase in depressive or anxious symptoms, and 6 of headaches.

**Section Summary: Obsessive-Compulsive Disorder**
The literature on deep brain stimulation for OCD includes RCTs and meta-analyses. Most studies had limited sample sizes and were at high risk of bias. Studies suggest that there may be improvements in OCD symptoms after deep brain stimulation treatment, but have also identified a substantial
number of adverse events and the optimal target(s) has not been determined. Additional blinded controlled studies are needed to draw conclusions about the impact of deep brain stimulation on the net health benefit.

**Other Neurologic and Psychiatric Disorders**

**Clinical Context and Therapy Purpose**

The role of deep brain stimulation in treatment of other treatment-resistant neurologic and psychiatric disorders, such as MS and chronic pain, is also being investigated. Ablative procedures are irreversible and, though they have been refined, remain controversial treatments for intractable illness. Interest has shifted to neuromodulation through deep brain stimulation of nodes or targets within neural circuits involved in these disorders. Currently, a variety of target areas are being studied.

The following PICO was used to select literature to inform this review.

**Populations**

The population of interest are individuals with anorexia nervosa, alcohol addiction, Alzheimer disease, Huntington disease, MS, or chronic pain.

**Interventions**

The therapy being considered is deep brain stimulation. Several targets have been investigated. Affective limbic structures include the ventral striatum/ventral capsule, anterior limb of the internal capsule, and subgenual cingulate cortex. Memory implicated structures include the fornix and nucleus basalis.

**Comparators**

Alternative treatments vary by condition, and generally include pharmacologic therapy, behavioral therapy, and psychotherapy. Sham deep brain stimulation is an appropriate comparator for RCTs.

**Outcomes**

Key efficacy outcomes include measures of symptoms severity, functional ability and disability, and quality of life.

Key safety outcomes include death, stroke, depression, cognition, infection, and other device and procedure related events.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

**Review of Evidence**

**Multiple Sclerosis**

**Systematic Review**

Brandmeir et al (2020) reported a meta-analysis of 13 studies of deep brain stimulation for MS tremor (129 patients received deep brain stimulation and 132 received medical management). Results were compared for tremor severity after deep brain stimulation versus tremor severity at baseline, and were combined across different target areas (ventral intermediate nucleus of the
thalamus, ventral oralis nucleus of the thalamus, ventral caudal nucleus of the thalamus, zona incerta) and different levels of evidence. Four studies were rated as level II evidence, but the studies were not randomized and the sample size was limited, ranging from 4 to 12 patients. Meta-analysis showed an improvement in the mean tremor score of 2.86 (95% CI, 2.03 to 3.70; \( p < .001 \)). However, heterogeneity was high, suggesting that meta-analysis is not appropriate, and no distinction was made for the different anatomical targets. There was also evidence of publication bias.

Section Summary: Multiple Sclerosis
The literature on deep brain stimulation for MS tremor is characterized by a few non-randomized trials with a limited sample size and a variety of brain targets. Only 1 of the controlled trials was conducted in the last decade. In addition to these limitations, there is evidence of publication bias on meta-analysis. Literature does not currently support deep brain stimulation for MS tremor.

Chronic Pain
Systematic Review
Deer et al (2020) conducted a systematic review of deep brain stimulation for chronic pain. They identified 1 RCT from 2017 that included 10 patients with post-stroke pain syndrome and 1 RCT from 2010 with 11 patients who had chronic cluster headaches (described above). Three early case series (1990 to 2017, \( n = 12 \) to 48) included patients with a variety of pain conditions, including phantom limb pain, cancer, brachial plexus injury, failed back surgery, and spinal cord injury. The location of the stimulation was variable. Publication bias was not assessed.

Section Summary: Chronic Pain
Literature on deep brain stimulation for chronic pain is characterized by older studies (2 RCTs and 3 case series), published between 1990 and 2017, with a wide range of pain conditions and variety of targets. A systematic review of the evidence did not evaluate publication bias, which is suggested by the low number and age of publications.

Alcohol Use Disorder
Randomized Controlled Trial
Bach et al (2023) conducted a multicenter, double-blind, RCT of deep brain stimulation to the nucleus accumbens in 12 patients with treatment-resistant alcohol use disorder. Deep brain stimulation was compared to sham stimulation over a 6 month period in hospitalized patients, followed by 12 months of unblinded treatment with deep brain stimulation in all patients. The primary outcome, continuous abstinence (i.e., time to first alcohol use), was not significantly different between groups (\( p = .619 \)), likely due to limited sample size/lack of power to find a difference. Secondary outcomes, including proportion of days abstinent (\( p = .048 \)), alcohol craving as measured by the Alcohol Urge Questionnaire (\( p = .02 \)), and anhedonia as measured by the Snaith-Hamilton Pleasure Scale (\( p = .028 \)) were improved at 6 months with the deep brain stimulation group compared to sham stimulation. The authors stated that larger studies are needed to confirm these results.

Section Summary: Alcohol Use Disorder
A RCT in patients with alcohol use disorder did not find a difference in time to first alcohol use. Larger studies are needed to confirm the efficacy of deep brain stimulation in this population.

Other Indications
An exploratory study of the safety and tolerability of deep brain stimulation of the nucleus basalis of Meynert in 6 patients with dementia with Lewy bodies was reported by Gratwicke et al (2020). Clinical outcomes were not evaluated. A pooled analysis by Shaffer et al (2023) of observational cohorts and case reports (\( n = 36 \)) of deep brain stimulation in patients with anorexia nervosa stated that there may be a benefit for deep brain stimulation to the subcallosal cingulate cortex in this population. The evidence on use of deep brain stimulation for Alzheimer disease, and Huntington disease consists of case series. These case series provide inadequate evidence on which to assess efficacy.
Supplemental Information
The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Clinical Input From Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2014 Input
In response to requests, input was received from 2 academic medical centers and 2 physician specialty societies while this policy was under review in 2014. Input supported the use of bilateral deep brain stimulation in individuals with medically unresponsive tremor in both limbs.

Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Academy of Neurology
Essential Tremor
In 2011, the American Academy of Neurology (AAN) updated its guidelines on the treatment of essential tremor, which were reaffirmed in 2022. This update did not change the conclusions and recommendations of the AAN (2005) practice parameters on deep brain stimulation for essential tremor. The guidelines stated that bilateral deep brain stimulation of the thalamic nucleus may be used to treat medically refractory limb tremor in both upper limbs (level C, possibly effective) but that there were insufficient data on the risk/benefit ratio of bilateral versus unilateral deep brain stimulation in the treatment of limb tremor. There was insufficient evidence to make recommendations on the use of thalamic deep brain stimulation for head or voice tremor (level U, treatment is unproven).

Parkinson Disease
In 2018, the AAN affirmed the guideline developed by the Congress of Neurological Surgeons (see Table 19).

Tourette Syndrome
Guidelines from AAN (2019, reaffirmed 2022) provide recommendations on the assessment for and use of deep brain stimulation in adults with severe, treatment-refractory tics. The AAN notes that patients with severe Tourette syndrome resistant to medical and behavioral therapy may benefit from deep brain stimulation, but there is no consensus on the optimal brain target. Brain regions that have been stimulated in patients with Tourette syndrome include the centromedian thalamus, the globus pallidus internus (ventral and dorsal), the globus pallidus externus, the subthalamic nucleus, and the ventral striatum/ventral capsular nucleus accumbens region. The AAN concludes that deep brain stimulation of the anteromedial globus pallidus is possibly more likely than sham stimulation to reduce tic severity.

American Society for Stereotactic and Functional Neurosurgery
Obsessive-Compulsive Disorder
In 2021, the American Society for Stereotactic and Functional Neurosurgery and the Congress of Neurological Surgeons updated their 2014 guidelines on deep brain stimulation for obsessive-compulsive disorder. The document concluded that there was a single level I study supporting the
use of bilateral subthalamic nucleus deep brain stimulation for medically refractory obsessive-compulsive disorder and a single level II study supporting bilateral nucleus accumbens or bed nucleus of stria terminalis deep brain stimulation for medically refractory obsessive-compulsive disorder. It also concluded that the evidence on unilateral deep brain stimulation was insufficient.

**Refractory Epilepsy**
In 2022, the American Society for Stereotactic and Functional Neurosurgery published a position statement on deep brain stimulation for medication-refractory epilepsy. Indications for deep brain stimulation include confirmed diagnosis of epilepsy (focal onset seizures with or without generalization), failure to achieve seizure control after 2 or more appropriately dosed seizure medications, seizures with localized onset in a region that cannot be resected or for which surgical resection has failed, or focal-onset seizures with a nonlocalized or unclear region of onset.

**Congress of Neurologic Surgeons**

**Parkinson Disease**
In 2018, evidence-based guidelines from the Congress of Neurologic Surgeons, affirmed by the AAN, compared the efficacy of bi-lateral deep brain stimulation of the subthalamic nucleus and globus pallidus internus for the treatment of patients with Parkinson disease.

<table>
<thead>
<tr>
<th>Table 22. Recommendations of the Congress of Neurologic Surgeons for DBS for Parkinson Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Goal</strong></td>
</tr>
<tr>
<td>Improving motor symptoms</td>
</tr>
<tr>
<td>Reduction of dopaminergic medication</td>
</tr>
<tr>
<td>Treatment of &quot;on&quot; medication dyskinesias</td>
</tr>
<tr>
<td>Quality of life</td>
</tr>
<tr>
<td>Lessen impact of DBS on cognitive decline</td>
</tr>
<tr>
<td>Reduce risk of depression</td>
</tr>
<tr>
<td>Reduce adverse effects</td>
</tr>
</tbody>
</table>

DBS: Deep brain stimulation

**National Institute for Health and Care Excellence**
The United Kingdom’s NICE has published guidance documents on deep brain stimulation, as discussed in the following subsections.

**Tremor and Dystonia**
In 2006, NICE made the same statements about use of deep brain stimulation for treatment of both tremor and dystonia. Unilateral and bilateral stimulation of structures responsible for modifying movements, such as the thalamus, globus pallidus, and the subthalamic nucleus, which interact functionally with the substantia nigra, are included in both guidance statements. The guidance stated: “Current evidence on the safety and efficacy of deep brain stimulation for tremor and dystonia (excluding Parkinson’s disease) appears adequate to support the use of this procedure.”

**Refractory Chronic Pain Syndromes (Excluding Headache)**
In 2011, guidance from NICE indicated there is evidence that deep brain stimulation for refractory chronic pain (excluding headache) is associated with serious risks. However, the procedure is “efficacious in some patients" refractory to other treatments.” Patients should be informed that deep
brain stimulation may not control their chronic pain symptoms and that possible risks associated with this procedure include the small risk of death.

**Intractable Trigeminal Autonomic Cephalalgias**
In 2011, guidance from NICE indicated that the evidence on the efficacy of deep brain stimulation for intractable trigeminal autonomic cephalalgias (e.g., cluster headaches) was "limited and inconsistent, and the evidence on safety shows that there were serious but well-known adverse effects."89

**Refractory Epilepsy**
In 2020, guidance from NICE indicated that the evidence on the efficacy and safety of deep brain stimulation for refractory epilepsy (for anterior thalamic targets) was limited in both quantity and quality, and "this procedure should only be used with special arrangements for clinical governance, consent, and audit or research."90 For targets other than the anterior thalamus, NICE recommends that "this procedure should only be used in the context of research".

**Parkinson Disease**
In 2003, NICE stated that the evidence on the safety and efficacy of deep brain stimulation for treatment of Parkinson disease "appears adequate to support the use of the procedure."91 The guidance noted that deep brain stimulation should only be offered when Parkinson disease is refractory to best medical treatment.

**U.S. Preventive Services Task Force Recommendations**
Not applicable.

**Medicare National Coverage**
Effective for services furnished in April 2003, Medicare covers unilateral or bilateral thalamic ventralis intermedius nucleus deep brain stimulation for the treatment of essential tumor and/or parkinsonian tremor and unilateral or bilateral subthalamic nucleus or globus pallidus interna deep brain stimulation for the treatment of Parkinson disease when the following conditions are met92:

1. Devices must be approved by the Food and Drug Administration (FDA) for “deep brain stimulation or devices used in accordance with FDA-approved protocols governing Category B Investigational Device Exemption (IDE) deep brain stimulation clinical trials.”

2. For thalamic ventralis intermedius nucleus deep brain stimulation, patients must meet all of the following criteria:
   a. “Diagnosis of ET [essential tremor] based on postural or kinetic tremors of hand(s) without other neurologic signs, or diagnosis of idiopathic Parkinson disease (presence of at least 2 cardinal PD [Parkinson disease] features (tremor, rigidity or bradykinesia)) which is of a tremor-dominant form.
   b. Marked disabling tremor of at least level 3 or 4 on the Fahn-Tolosa-Marin Clinical Tremor Rating Scale (or equivalent scale) in the extremity intended for treatment, causing significant limitation in daily activities despite optimal medical therapy.
   c. Willingness and ability to cooperate during conscious operative procedure, as well as during postsurgical evaluations, adjustments of medications and stimulator settings.”

3. For subthalamic nucleus or globus pallidus interna deep brain stimulation, patients must meet all of the following criteria:
   a. “Diagnosis of PD based on the presence of at least 2 cardinal Parkinson disease features (tremor, rigidity or bradykinesia).
   b. Advanced idiopathic PD as determined by the use of Hoehn and Yahr stage or Unified Parkinson’s Disease Rating Scale part III motor subscale.
   c. L-dopa responsive with clearly defined ‘on’ periods.
   d. Persistent disabling Parkinson’s symptoms or drug side effects (e.g., dyskinesias, motor fluctuations, or disabling ‘off’ periods) despite optimal medical therapy.
   e. Willingness and ability to cooperate during conscious operative procedure, as well as during post-surgical evaluations, adjustments of medications and stimulator settings.”
Deep brain stimulation is not covered for essential tumor or Parkinson disease patients with any of the following:

1. “Non-idiopathic Parkinson’s disease or ‘Parkinson’s Plus’ syndromes.
2. Cognitive impairment, dementia or depression, which would be worsened by or would interfere with the patient's ability to benefit from DBS [deep brain stimulation].
3. Current psychosis, alcohol abuse or other drug abuse.

Structural lesions such as basal ganglionic stroke, tumor or vascular malformation as etiology of the movement disorder.

Previous movement disorder surgery within the affected basal ganglion.

Significant medical, surgical, neurologic or orthopedic co-morbidities contraindicating DBS [deep brain stimulation] surgery or stimulation.

### Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 23. Included are randomized controlled trials with at least 40 participants, excluding trials on deep brain stimulation for Parkinson disease.

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ongoing</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Epilepsy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT04181229</td>
<td>Deep Brain Stimulation After Failed Vagal Nerve Stimulation for the Treatment of Drug-Resistant Epilepsy in Children</td>
<td>50</td>
<td>Mar 2025</td>
</tr>
<tr>
<td>NCT04164056</td>
<td>Hippocampal and Thalamic deep brain stimulation for Bilateral Temporal Lobe Epilepsy</td>
<td>80</td>
<td>Sep 2024</td>
</tr>
<tr>
<td>NCT03900468</td>
<td>Medtronic Deep Brain Stimulation Therapy for Epilepsy Post-Approval Study (EPAS)</td>
<td>140</td>
<td>Mar 2028</td>
</tr>
<tr>
<td></td>
<td>Huntington’s Disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT04244513</td>
<td>Deep Brain Stimulation Treatment for Chorea in Huntington’s Disease</td>
<td>40</td>
<td>Dec 2023</td>
</tr>
<tr>
<td></td>
<td>Obsessive-Compulsive Disorder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02773082</td>
<td>Reclaim Deep Brain Stimulation Therapy for Obsessive-Compulsive Disorder (OCD)</td>
<td>50</td>
<td>Jan 2030</td>
</tr>
<tr>
<td>NCT02844049</td>
<td>European Study of Quality of Life in Resistant OCD Patients Treated by subthalamic nucleus deep brain stimulation</td>
<td>60</td>
<td>Dec 2026</td>
</tr>
<tr>
<td></td>
<td>Treatment Resistant Depression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT05653858</td>
<td>Controlled Randomized Clinical Trial to Assess Efficacy of Deep Brain Stimulation of the sIMFB in Patients With Treatment Resistant Major Depression (FORSEEIII)</td>
<td>47</td>
<td>Jun 2025</td>
</tr>
<tr>
<td></td>
<td>Alzheimer Disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT03622905</td>
<td>ADvance II Study: DBS-f in Patients With Mild Alzheimer’s Disease</td>
<td>210</td>
<td>Oct 2026</td>
</tr>
<tr>
<td></td>
<td>Unpublished</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02076698</td>
<td>Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy</td>
<td>62</td>
<td>Nov 2021</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

* Denotes industry-sponsored or cosponsored trial.
References


Documentation for Clinical Review

Please provide the following documentation:
- History and physical including: diagnosis and chronic history
- Pharmacological treatment: including type of drug(s), dosage, duration of use, and responses (if applicable)
- Reason for requesting deep brain stimulation
- Motor portion of the Unified Parkinson Disease Rating Scale when the patient has been without medication for approximately 12 hours if applicable

Post Service (in addition to the above, please include the following):
- Operative report(s)

### Coding

*This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy.*

The following codes are included below for informational purposes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement policy. Policy Statements are intended to provide member coverage information and may include the use of some codes for clarity. The Policy Guidelines section may also provide additional information for how to interpret the Policy Statements and to provide coding guidance in some cases.

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>61850</td>
<td>Twist drill or burr hole(s) for implantation of neurostimulator electrodes, cortical</td>
</tr>
<tr>
<td></td>
<td>61863</td>
<td>Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (e.g., thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), without use of intraoperative microelectrode recording; first array</td>
</tr>
<tr>
<td></td>
<td>61864</td>
<td>Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (e.g., thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), without use of intraoperative microelectrode recording; each additional array (List separately in addition to primary procedure)</td>
</tr>
<tr>
<td></td>
<td>61867</td>
<td>Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (e.g., thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), with use of intraoperative microelectrode recording; first array</td>
</tr>
<tr>
<td></td>
<td>61868</td>
<td>Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (e.g., thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), with use of intraoperative microelectrode recording; each additional array (List separately in addition to primary procedure)</td>
</tr>
<tr>
<td></td>
<td>61885</td>
<td>Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array</td>
</tr>
<tr>
<td></td>
<td>61886</td>
<td>Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to 2 or more electrode arrays</td>
</tr>
<tr>
<td></td>
<td>95970</td>
<td>Electronic analysis of implanted neurostimulator pulse generator/transmitter (e.g., contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose</td>
</tr>
<tr>
<td>Type</td>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain, cranial nerve, spinal cord, peripheral nerve, or sacral nerve, neurostimulator pulse generator/transmitter, without programming</td>
</tr>
<tr>
<td></td>
<td>95983</td>
<td>Electronic analysis of implanted neurostimulator pulse generator/transmitter (e.g., contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, first 15 minutes face-to-face time with physician or other qualified health care professional</td>
</tr>
<tr>
<td></td>
<td>95984</td>
<td>Electronic analysis of implanted neurostimulator pulse generator/transmitter (e.g., contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, each additional 15 minutes face-to-face time with physician or other qualified health care professional (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>HCPCS</td>
<td>L8680</td>
<td>Implantable neurostimulator electrode, each</td>
</tr>
<tr>
<td></td>
<td>L8685</td>
<td>Implantable neurostimulator pulse generator, single array, rechargeable, includes extension</td>
</tr>
<tr>
<td></td>
<td>L8686</td>
<td>Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension</td>
</tr>
<tr>
<td></td>
<td>L8687</td>
<td>Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension</td>
</tr>
<tr>
<td></td>
<td>L8688</td>
<td>Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension</td>
</tr>
</tbody>
</table>

**Policy History**

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/18/2009</td>
<td>New policy</td>
</tr>
<tr>
<td></td>
<td>Portions of this policy have been derived from the previously existing BSC Medical Policy Bilateral Deep Brain Stimulation for Parkinsons disease and Essential Tremor, and Deep Brain Stimulation of the Thalamus for Tremor</td>
</tr>
<tr>
<td>10/29/2010</td>
<td>Coding Update</td>
</tr>
<tr>
<td>03/13/2012</td>
<td>Coding Update</td>
</tr>
<tr>
<td>08/07/2013</td>
<td>Policy revision without position change. Policy placed on No Further Routine Literature Review and Update status</td>
</tr>
<tr>
<td>02/27/2014</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>09/30/2015</td>
<td>Coding Update</td>
</tr>
<tr>
<td>02/01/2016</td>
<td>Coding update</td>
</tr>
<tr>
<td>07/01/2016</td>
<td>Policy revision without position change</td>
</tr>
</tbody>
</table>
**Definitions of Decision Determinations**

**Medically Necessary:** Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member’s illness, injury, or disease.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

**Prior Authorization Requirements and Feedback (as applicable to your plan)**

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member’s health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member’s eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at [www.blueshieldca.com/provider](http://www.blueshieldca.com/provider).

We are interested in receiving feedback relative to developing, adopting, and reviewing criteria for medical policy. Any licensed practitioner who is contracted with Blue Shield of California or Blue Shield of California Promise Health Plan is welcome to provide comments, suggestions, or concerns. Our internal policy committees will receive and take your comments into consideration.

For utilization and medical policy feedback, please send comments to: [MedPolicy@blueshieldca.com](mailto:MedPolicy@blueshieldca.com)

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must
be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield
reserves the right to review and update policies as appropriate.
<table>
<thead>
<tr>
<th>BEFORE</th>
<th>AFTER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reactivated Policy</td>
<td><strong>Deep Brain Stimulation 7.01.63</strong></td>
</tr>
<tr>
<td><strong>Policy Statement:</strong> N/A</td>
<td><strong>Policy Statement:</strong></td>
</tr>
</tbody>
</table>

I. Unilateral deep brain stimulation of the thalamus may be considered **medically necessary** in individuals with disabling, medically unresponsive tremor due to essential tremor or Parkinson disease.

II. Bilateral deep brain stimulation of the thalamus may be considered **medically necessary** in individuals with disabling, medically unresponsive tremor in both upper limbs due to essential tremor or Parkinson disease.

III. Unilateral or bilateral deep brain stimulation of the globus pallidus or subthalamic nucleus may be considered **medically necessary** in the following individuals:

   A. Those with Parkinson disease and **all** of the following:
      1. A good response to levodopa
      2. Motor complications not controlled by pharmacologic therapy
      3. **One** of the following:
         a. A minimum score of 30 points on the motor portion of the Unified Parkinson Disease Rating Scale when the patient has been without medication for approximately 12 hours
         b. Parkinson disease for at least 4 years
   B. Individuals older than 7 years with chronic, intractable (drug-refractory) primary dystonia, including generalized and/or segmental dystonia, hemidystonia, and cervical dystonia (torticollis)

IV. Deep brain stimulation for other movement disorders, including but not limited to tardive dyskinesia and post-traumatic dyskinesia, is considered **investigational**.
| POLICY STATEMENT |
|------------------|-------------------------|
| BEFORE | AFTER |
| | **Blue font: Verbiage Changes/Additions** |
| | V. Deep brain stimulation for the treatment of chronic cluster headaches is considered *investigational*. |
| | VI. Deep brain stimulation for the treatment of other psychiatric or neurologic disorders, including but not limited to epilepsy, Tourette syndrome, depression, obsessive-compulsive disorder, anorexia nervosa, alcohol addiction, Alzheimer disease, multiple sclerosis tremor, and chronic pain, is considered *investigational*. |